

Intraepithelial Carcinoma of the Fimbria and Pelvic Serosa Causal Relationship

American Journal of Surgical Pathology

31, 161-169

DOI: [10.1097/01.pas.0000213335.40358.47](https://doi.org/10.1097/01.pas.0000213335.40358.47)

Citation Report

#	ARTICLE	IF	CITATIONS
1	My approach to and thoughts on the typing of ovarian carcinomas. <i>Journal of Clinical Pathology</i> , 2007, 61, 152-163.	1.0	141
2	CA125 in ovarian cancer. <i>Biomarkers in Medicine</i> , 2007, 1, 513-523.	0.6	164
3	Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2007, 25, 3985-3990.	0.8	453
4	Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer. <i>Clinical Medicine and Research</i> , 2007, 5, 35-44.	0.4	301
5	HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. <i>Histopathology</i> , 2007, 51, 666-673.	1.6	17
6	Fallopian Tube Cancer: Stepchild or Mother?. <i>Gynecologic Oncology</i> , 2007, 107, 386-387.	0.6	1
7	Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. <i>Diagnostic Histopathology</i> , 2008, 14, 352-365.	0.2	28
8	Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 351-356.	0.7	178
9	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. <i>Modern Pathology</i> , 2008, 21, 676-684.	2.9	91
10	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. <i>Histopathology</i> , 2008, 53, 127-138.	1.6	89
11	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. <i>Gynecologic Oncology</i> , 2008, 108, 652-657.	0.6	21
12	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. <i>Gynecologic Oncology</i> , 2008, 109, 168-173.	0.6	268
13	Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, 408-417.	0.6	113
14	The origin of ovarian carcinomas: A developmental view. <i>Gynecologic Oncology</i> , 2008, 110, 452-454.	0.6	67
15	Risk factors for a serous cancer precursor (p53 signature) in women with inherited BRCA mutations. <i>Gynecologic Oncology</i> , 2008, 111, 226-232.	0.6	77
16	Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. <i>Lancet Oncology</i> , The, 2008, 9, 1076-1085.	5.1	97
17	Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1566-1571.	2.1	263
18	Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. <i>Molecular Cancer Research</i> , 2008, 6, 1678-1690.	1.5	108

#	ARTICLE	IF	CITATIONS
19	Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2008, 26, 4160-4165.	0.8	317
20	Early Events in the Pathogenesis of Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 995-1005.	0.8	388
21	Critical molecular abnormalities in high-grade serous carcinoma of the ovary. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e22.	1.6	48
22	Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from <i>BRCA</i> Mutation Carriers Resemble High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 4067-4078.	3.2	129
23	Pathogenesis of Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2008, PAP, 151-60.	0.9	385
25	New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. <i>Journal of Clinical Oncology</i> , 2008, 26, 5284-5293.	0.8	362
26	Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 2263-2269.	3.2	111
27	Adenofibroma of the Fimbria: A Common Entity That Is Indistinguishable From Ovarian Adenofibroma. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 390-397.	0.9	40
28	Serous Carcinogenesis in the Fallopian Tube. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 1-9.	0.9	275
29	Low-grade Serous Carcinoma of the Ovary Displaying a Macropapillary Pattern of Invasion. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1800-1806.	2.1	32
30	MicroRNA Profiling of <i>BRCA1/2</i> Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary. <i>PLoS ONE</i> , 2009, 4, e7314.	1.1	83
31	Ovarian Low-grade and High-grade Serous Carcinoma. <i>Advances in Anatomic Pathology</i> , 2009, 16, 267-282.	2.4	477
32	Ovarian Cancer Screening and Early Detection. <i>Women's Health</i> , 2009, 5, 693-699.	0.7	16
33	The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection. <i>PLoS Medicine</i> , 2009, 6, e1000114.	3.9	205
34	The Standard of Perfection: Thoughts about the Laying Hen Model of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 97-99.	0.7	20
35	Expression of ovarian tumour suppressor <i>OPCML</i> in the female CD-1 mouse reproductive tract. <i>Reproduction</i> , 2009, 137, 721-726.	1.1	1
36	Precursors to pelvic serous carcinoma and their clinical implications. <i>Gynecologic Oncology</i> , 2009, 113, 391-396.	0.6	104
37	Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 3-11.	0.6	57

#	ARTICLE	IF	CITATIONS
38	The Unique Characteristics of Ovarian Carcinogenesis in the Adolescent and Young Adult Population. <i>Seminars in Oncology</i> , 2009, 36, 250-257.	0.8	2
39	Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: Fact or artifact?. <i>International Journal of Cancer</i> , 2009, 124, 2231-2235.	2.3	27
41	Recent advances in molecular gynaecological pathology. <i>Histopathology</i> , 2009, 55, 243-249.	1.6	14
42	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. <i>Modern Pathology</i> , 2009, 22, 197-205.	2.9	80
43	Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. <i>Modern Pathology</i> , 2009, 22, 345-350.	2.9	61
44	Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. <i>Modern Pathology</i> , 2009, 22, 985-988.	2.9	43
45	Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. <i>Modern Pathology</i> , 2009, 22, 1133-1138.	2.9	197
46	Gynaecological cancers in genetically susceptible women: new thoughts on tubal pathology. <i>Diagnostic Histopathology</i> , 2009, 15, 545-553.	0.2	4
47	The Mammalian Ovary from Genesis to Revelation. <i>Endocrine Reviews</i> , 2009, 30, 624-712.	8.9	630
48	Discriminative MRI features of fallopian tube masses. <i>Clinical Radiology</i> , 2009, 64, 815-831.	0.5	24
49	Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. <i>Cancer Letters</i> , 2009, 278, 56-64.	3.2	38
50	Ovarian carcinoma pathology and genetics: recent advances. <i>Human Pathology</i> , 2009, 40, 1213-1223.	1.1	211
51	Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. <i>Molecular Oncology</i> , 2009, 3, 165-170.	2.1	143
52	Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. <i>Molecular Oncology</i> , 2009, 3, 97-137.	2.1	171
53	CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2009, 2, 86-89.	0.2	0
54	A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report. <i>Diagnostic Pathology</i> , 2009, 4, 43.	0.9	2
55	Ovarian Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 287-313.	9.6	576
56	Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs. <i>Biomarkers in Medicine</i> , 2009, 3, 743-756.	0.6	13

#	ARTICLE	IF	CITATIONS
57	Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass. <i>American Journal of Surgical Pathology</i> , 2009, 33, 376-383.	2.1	126
58	Multistep Level Sections to Detect Occult Fallopian Tube Carcinoma in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1878-1885.	2.1	92
59	Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 308-315.	0.9	86
60	The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 58-64.	1.2	181
61	miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 641-647.	1.2	55
62	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. <i>Cell Cycle</i> , 2010, 9, 140-146.	1.3	21
63	A Unique Case of Primary Squamous Carcinoma of the Salpinx Associated With Serous Carcinoma of the Omentum. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 533-538.	0.9	4
64	Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy. <i>Obstetrics and Gynecology</i> , 2010, 116, 733-743.	1.2	89
65	The pathology of and controversial aspects of ovarian borderline tumours. <i>Current Opinion in Oncology</i> , 2010, 22, 462-472.	1.1	52
66	A Pathologist's Road Map to Benign, Precancerous, and Malignant Intraepithelial Proliferations in the Fallopian Tube. <i>Advances in Anatomic Pathology</i> , 2010, 17, 293-302.	2.4	77
67	Bilateral Microscopic Adenocarcinoma of the Fallopian Tubes Detected by an Endometrial Cytologic Smear. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 273-277.	0.9	11
68	Serous Tubal Intraepithelial Carcinoma: Diagnostic Reproducibility and its Implications. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 310-314.	0.9	83
69	Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1407-1416.	2.1	395
70	The Endocervical Origin of HPV-positive Mucinous/Endometrioid Ovarian Tumors Remains Unproven. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 298-300.	0.9	2
71	Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 829-836.	2.1	127
72	Genetic/Familial High-Risk Assessment: Breast and Ovarian. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 562-594.	2.3	253
73	Primary Serous Peritoneal Carcinoma Presenting First on a Routine Papanicolaou Smear. <i>Acta Cytologica</i> , 2010, 54, 623-626.	0.7	7
74	Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 597-608.	1.4	25

#	ARTICLE	IF	CITATIONS
75	Microenvironment and Pathogenesis of Epithelial Ovarian Cancer. <i>Hormones and Cancer</i> , 2010, 1, 277-290.	4.9	65
76	Classification of ovarian carcinomas based on pathology and molecular genetics. <i>Clinical and Translational Oncology</i> , 2010, 12, 783-787.	1.2	9
77	Expression signatures of TP53 mutations in serous ovarian cancers. <i>BMC Cancer</i> , 2010, 10, 237.	1.1	46
78	Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?. <i>Gynecologic Oncology</i> , 2010, 117, 27-31.	0.6	21
79	SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance. <i>Gynecologic Oncology</i> , 2010, 119, 7-17.	0.6	139
80	The molecular pathogenesis of hereditary ovarian carcinoma. <i>Cancer</i> , 2010, 116, 5261-5271.	2.0	92
81	Bringing the p53 signature into focus. <i>Cancer</i> , 2010, 116, 5119-5121.	2.0	11
82	The Li€Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. <i>Journal of Pathology</i> , 2010, 220, 17-23.	2.1	41
83	The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. <i>Journal of Pathology</i> , 2010, 220, 5-6.	2.1	30
84	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. <i>Journal of Pathology</i> , 2010, 220, 392-400.	2.1	92
85	Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. <i>Journal of Pathology</i> , 2010, 222, 110-116.	2.1	129
86	Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. <i>Oncogene</i> , 2010, 29, 1103-1113.	2.6	187
87	The genesis and evolution of high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 803-808.	12.8	360
88	Ovarian Cancer Pathogenesis: A Model in Evolution. <i>Journal of Oncology</i> , 2010, 2010, 1-13.	0.6	204
89	Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics. <i>Journal of Oncology</i> , 2010, 2010, 1-9.	0.6	64
90	Molecular Genetic Markers in Female Reproductive Cancers. <i>Journal of Oncology</i> , 2010, 2010, 1-2.	0.6	1
91	The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. <i>American Journal of Surgical Pathology</i> , 2010, 34, 433-443.	2.1	1,503
92	Emerging drugs for ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 635-652.	1.0	4

#	ARTICLE	IF	CITATIONS
93	High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. <i>Modern Pathology</i> , 2010, 23, 1316-1324.	2.9	109
94	Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. <i>Modern Pathology</i> , 2010, 23, 844-855.	2.9	84
95	Identification of a Preneoplastic Gene Expression Profile in Tubal Epithelium of BRCA1 Mutation Carriers. <i>Neoplasia</i> , 2010, 12, 993-IN8.	2.3	22
96	Novel Surgical Approaches for Sampling the Ovarian Surface Epithelium and Proximal Fluid Proteome. <i>Journal of Proteome Research</i> , 2010, 9, 6071-6076.	1.8	11
97	Ovarian Cancer Development and Metastasis. <i>American Journal of Pathology</i> , 2010, 177, 1053-1064.	1.9	1,312
98	Immunohistology of the Female Genital Tract. , 2010, , 690-762.		9
99	Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype. <i>American Journal of Epidemiology</i> , 2010, 171, 45-53.	1.6	188
100	Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14240-14245.	3.3	113
102	CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 86-89.	0.2	0
103	Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum. <i>Surgical Pathology Clinics</i> , 2011, 4, 461-478.	0.7	1
104	Ultrasound and Ovarian Cancer Screening: Is There a Future?. <i>Journal of Minimally Invasive Gynecology</i> , 2011, 18, 24-30.	0.3	8
105	Molecular Pathology of Ovarian Carcinomas. <i>Surgical Pathology Clinics</i> , 2011, 4, 275-296.	0.7	1
106	Surface Epithelial Tumors of the Ovary. , 2011, , 679-784.		62
107	Primary peritoneal serous carcinoma with signet ring cells. <i>Gynecologic Oncology Case Reports</i> , 2011, 1, 4-5.	0.9	2
108	The post-reproductive Fallopian tube: better removed?. <i>Human Reproduction</i> , 2011, 26, 2918-2924.	0.4	91
109	Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior. <i>Human Pathology</i> , 2011, 42, 833-839.	1.1	9
110	Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm. <i>Human Pathology</i> , 2011, 42, 918-931.	1.1	932
111	Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary. <i>Journal of Gynecologic Oncology</i> , 2011, 22, 9.	1.0	7

#	ARTICLE	IF	CITATIONS
112	Morphological sub-types of ovarian carcinoma: new developments and pathogenesis. , 0, , 3-16.		1
113	Predictive biology of ovarian cancer. , 0, , 41-54.		0
114	Ovarian Epithelial Cancer Stem Cells. Scientific World Journal, The, 2011, 11, 1243-1269.	0.8	17
115	Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics, 2011, 66, 73-76.	0.6	23
116	STICS SCOUTs and p53 signatures a new language for pelvic serous carcinogenesis. Frontiers in Bioscience - Elite, 2011, E3, 625-634.	0.9	90
117	Screening for ovarian cancer: Old tools, new lessons. Cancer Biomarkers, 2011, 8, 177-186.	0.8	9
118	Fallopian Tube Correlates of Ovarian Serous Borderline Tumors. American Journal of Surgical Pathology, 2011, 35, 1759-1765.	2.1	59
119	p53 Signature and Serous Tubal In-situ Carcinoma in Cases of Primary Tubal and Peritoneal Carcinomas and Serous Borderline Tumors of the Ovary. International Journal of Gynecological Pathology, 2011, 30, 417-424.	0.9	52
120	A Proposed Model for Endometrial Serous Carcinogenesis. American Journal of Surgical Pathology, 2011, 35, e1-e14.	2.1	97
121	Papillary Tubal Hyperplasia. American Journal of Surgical Pathology, 2011, 35, 1605-1614.	2.1	140
122	Junctional Epithelial Zones of the Fallopian Tube. International Journal of Gynecological Pathology, 2011, 30, 1-3.	0.9	7
123	The Origin of Ovarian Carcinomas. International Journal of Gynecological Pathology, 2011, 30, 12-21.	0.9	124
124	Serous Carcinoma of the Fallopian Tube Presenting as Axillary Lymphadenopathy. International Journal of Gynecological Pathology, 2011, 30, 53-57.	0.9	7
125	Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology, 2011, 43, 420-432.	0.3	401
126	Epithelial Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 82-113.	2.3	89
127	Response to Gilks et al. Modern Pathology, 2011, 24, 1282-1283.	2.9	3
128	Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 814-824.	1.1	114
129	The forgotten fallopian tube. Nature Reviews Cancer, 2011, 11, 227-227.	12.8	14

#	ARTICLE	IF	CITATIONS
130	Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. <i>Oncogene</i> , 2011, 30, 3522-3536.	2.6	66
131	Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. <i>Gynecologic Oncology</i> , 2011, 120, 385-392.	0.6	50
132	Low-grade serous primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2011, 121, 482-486.	0.6	42
133	Comparison of candidate serologic markers for type I and type II ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 560-566.	0.6	50
134	Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 19.e1-19.e6.	0.7	65
136	Identification of abrogated pathways in fallopian tube epithelium from <i>BRCA1</i> mutation carriers. <i>Journal of Pathology</i> , 2011, 225, 106-117.	2.1	33
137	Ovarian borderline tumours: a review with emphasis on controversial areas. <i>Diagnostic Histopathology</i> , 2011, 17, 178-192.	0.2	2
138	Tubal origin of "ovarian" low-grade serous carcinoma. <i>Modern Pathology</i> , 2011, 24, 1488-1499.	2.9	136
139	Early Diagnosis of Ovarian Carcinoma: Is a Solution in Sight?. <i>Radiology</i> , 2011, 259, 329-345.	3.6	82
140	Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. <i>Modern Pathology</i> , 2011, 24, 846-854.	2.9	26
141	The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. <i>Modern Pathology</i> , 2011, 24, 152-156.	2.9	41
142	The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention. <i>Human Reproduction</i> , 2011, 26, 2262-2273.	0.4	107
143	Diagnostic Pathology of Ovarian Tumors. , 2011, , .		6
144	<i>Chlamydia trachomatis</i> and <i>Mycoplasma genitalium</i> Plasma Antibodies in Relation to Epithelial Ovarian Tumors. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2011, 2011, 1-10.	0.4	48
145	Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?. <i>Clinical Cancer Research</i> , 2011, 17, 7273-7282.	3.2	23
146	Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7547-7552.	3.3	249
147	Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma. <i>Endocrine-Related Cancer</i> , 2011, 18, 221-34.	1.6	14
148	Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement. <i>Human Reproduction</i> , 2011, 26, 1422-1430.	0.4	12

#	ARTICLE	IF	CITATIONS
149	Infertility as a risk factor of ovarian and breast cancer. Expert Review of Obstetrics and Gynecology, 2011, 6, 153-161.	0.4	0
150	Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers. ISRN Obstetrics & Gynecology, 2011, 2011, 1-8.	1.2	14
151	Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings. Journal of Clinical Pathology, 2012, 65, 293-301.	1.0	31
152	Ovarian Cancer Stroma: Pathophysiology and the Roles in Cancer Development. Cancers, 2012, 4, 701-724.	1.7	24
153	High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3921-3926.	3.3	327
154	Frequency of Serous Tubal Intraepithelial Carcinoma in Various Gynecologic Malignancies. International Journal of Gynecological Pathology, 2012, 31, 103-110.	0.9	100
155	Ki-67 Labeling Index as an Adjunct in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 416-422.	0.9	50
156	Ovarian Cancer. Clinical Obstetrics and Gynecology, 2012, 55, 3-23.	0.6	275
157	The Oviduct and Ovarian Cancer. Clinical Obstetrics and Gynecology, 2012, 55, 24-35.	0.6	65
158	Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 243-253.	0.9	125
159	Digital quantification of precursor frequency in the fallopian tube and its significance. Modern Pathology, 2012, 25, 1654-1661.	2.9	8
160	PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Modern Pathology, 2012, 25, 449-455.	2.9	47
161	Murine models of ovarian cancer for preclinical testing of targeted therapeutics: Has their time arrived?. Cell Cycle, 2012, 11, 430-431.	1.3	2
162	Stem-Like Epithelial Cells Are Concentrated in the Distal End of the Fallopian Tube: A Site for Injury and Serous Cancer Initiation. Stem Cells, 2012, 30, 2487-2497.	1.4	155
163	New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. Gynecological Endocrinology, 2012, 28, 582-586.	0.7	12
165	Pre-Invasive Ovarian Mucinous Tumors Are Characterized by <i>CDKN2A</i> and <i>RAS</i> Pathway Aberrations. Clinical Cancer Research, 2012, 18, 5267-5277.	3.2	57
166	Targeting the epigenome in ovarian cancer. Future Oncology, 2012, 8, 151-164.	1.1	15
167	Ovarian Cancer: Prevention, Detection, and Treatment of the Disease and its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report. International Journal of Gynecological Cancer, 2012, 22, S45-S57.	1.2	43

#	ARTICLE	IF	CITATIONS
168	Low-Grade Ovarian Serous Neoplasms (Low-Grade Serous Carcinoma and Serous Borderline Tumor) Associated With High-Grade Serous Carcinoma or Undifferentiated Carcinoma. American Journal of Surgical Pathology, 2012, 36, 368-375.	2.1	75
170	It Sounded Like a Good Idea at the Time. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1127-1130.	0.3	14
172	Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy. International Journal of Gynecological Cancer, 2012, 22, 881-888.	1.2	7
173	BRCA, the Oviduct, and the Space and Time Continuum of Pelvic Serous Carcinogenesis. International Journal of Gynecological Cancer, 2012, 22, S29-S34.	1.2	49
174	It Sounded Like a Good Idea at the Time . . . Journal of Obstetrics and Gynaecology Canada, 2012, 34, 611-612.	0.3	12
175	Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma. Oncology Letters, 2012, 4, 1008-1012.	0.8	1
176	Prevention of ovarian cancer "let's do something. Acta Obstetrica Et Gynecologica Scandinavica, 2012, 91, 1009-1010.	1.3	7
177	Screening of symptomatic women for ovarian cancer. Lancet Oncology, The, 2012, 13, e137.	5.1	0
178	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2012, 119, S118-29.	1.0	194
180	Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecologic Oncology, 2012, 127, 88-93.	0.6	61
181	New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research. Gynecologic Oncology, 2012, 127, 645-650.	0.6	10
182	Epidemiología de los tumores del ovario. EMC - Ginecología-Obstetricia, 2012, 48, 1-10.	0.0	0
185	Fallopian Tube Cancer. , 2012, , 357-368.e5.		0
186	Molecular-targeted therapies for ovarian cancer: prospects for the future. International Journal of Clinical Oncology, 2012, 17, 424-429.	1.0	28
187	Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene, 2012, 31, 4987-4995.	2.6	16
188	<i>E2F3b</i> overexpression in ovarian carcinomas and in <i>BRCA1</i> Haploinsufficient fallopian tube epithelium. Genes Chromosomes and Cancer, 2012, 51, 1054-1062.	1.5	2
189	Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle, 2012, 11, 2107-2113.	1.3	36
190	Ovarian cancer stem cells: elusive targets for chemotherapy. Medical Oncology, 2012, 29, 3400-3408.	1.2	19

#	ARTICLE	IF	CITATIONS
191	Ovarian Cancer: Opportunity for Targeted Therapy. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	32
192	DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression. <i>Journal of Oncology</i> , 2012, 2012, 1-7.	0.6	16
193	Hox Gene Expression in Ovarian Cancer. <i>Annals of Oncology</i> , 2012, 23, ix68.	0.6	0
194	Ovarian Cancer is an Imported Disease: Fact or Fiction?. <i>Current Obstetrics and Gynecology Reports</i> , 2012, 1, 1-9.	0.3	105
195	Ovarian cancer and the pelvic floor surgeon: the case for prophylactic bilateral salpingectomy during POP surgery. <i>International Urogynecology Journal</i> , 2012, 23, 655-656.	0.7	13
196	Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 237-249.	1.4	442
197	Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 207-219.	1.1	32
198	The origin of ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 134-136.	1.1	14
199	HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. <i>Histopathology</i> , 2012, 60, 547-553.	1.6	25
200	Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). <i>Histopathology</i> , 2012, 61, 329-339.	1.6	17
201	Fallopian tube metastases of non-gynaecological origin: a series of 20 cases emphasizing patterns of involvement including intra-epithelial spread. <i>Histopathology</i> , 2012, 60, E106-14.	1.6	35
202	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 35-46.	2.0	27
203	Tumores primitivos de la trompa de Falopio. <i>EMC - GinecologÃa-Obstetricia</i> , 2012, 48, 1-9.	0.0	0
204	Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. <i>Journal of Hematology and Oncology</i> , 2012, 5, 8.	6.9	101
205	Origin of Ovarian Cancer: Molecular Profiling. <i>Journal of Obstetrics and Gynecology of India</i> , 2013, 63, 152-157.	0.3	9
206	Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. <i>Human Pathology</i> , 2013, 44, 2373-2384.	1.1	50
207	Molecular Surgical Pathology. , 2013, , .		23
208	Management of Gynecological Cancers in Older Women. , 2013, , .		2

#	ARTICLE	IF	CITATIONS
209	The DNA Methylomes of Serous Borderline Tumors Reveal Subgroups With Malignant- or Benign-Like Profiles. <i>American Journal of Pathology</i> , 2013, 182, 668-677.	1.9	13
210	Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions. <i>Clinical Cancer Research</i> , 2013, 19, 2873-2882.	3.2	36
211	miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrin $\beta 5$ Expression. <i>American Journal of Pathology</i> , 2013, 182, 1876-1889.	1.9	98
212	Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?. <i>Human Pathology</i> , 2013, 44, 1534-1543.	1.1	27
213	Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. <i>Annals of Oncology</i> , 2013, 24, x16-x21.	0.6	247
214	Type I to Type II Ovarian Carcinoma Progression. <i>American Journal of Pathology</i> , 2013, 182, 1391-1399.	1.9	54
215	The Molecular Fingerprint of High Grade Serous Ovarian Cancer Reflects Its Fallopian Tube Origin. <i>International Journal of Molecular Sciences</i> , 2013, 14, 6571-6596.	1.8	33
216	Physician Opinions Regarding Elective Bilateral Salpingectomy With Hysterectomy and for Sterilization. <i>Journal of Minimally Invasive Gynecology</i> , 2013, 20, 517-521.	0.3	48
217	Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15885-15909.	1.8	105
218	Biomarkers for Early Detection of Ovarian Cancer. <i>Women's Health</i> , 2013, 9, 171-187.	0.7	53
219	The role of the fallopian tube in the origin of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 409-414.	0.7	238
220	<i>Ovar.</i> , 2013, , 429-493.		0
222	Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: The time has come. <i>Gynecologic Oncology</i> , 2013, 129, 443-444.	0.6	19
223	Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2013, 130, 674-681.	0.6	71
224	Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2013, 129, 364-371.	0.6	79
225	KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants. <i>BMC Cancer</i> , 2013, 13, 483.	1.1	10
226	Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry. <i>Familial Cancer</i> , 2013, 12, 719-740.	0.9	11
227	Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 52-58.	0.6	57

#	ARTICLE	IF	CITATIONS
228	The hen as a model of ovarian cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 432-436.	12.8	113
229	Coming into focus: the nonovarian origins of ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, viii28-viii35.	0.6	75
230	A Critical Evaluation of the Evidence for Ovarian Conservation Versus Removal at the Time of Hysterectomy for Benign Disease. <i>Journal of Women's Health</i> , 2013, 22, 755-759.	1.5	12
231	Fertility drug use and risk of ovarian tumors: a debated clinical challenge. <i>Gynecological Endocrinology</i> , 2013, 29, 30-35.	0.7	18
232	Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 71-76.	0.6	8
235	Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 21-34.	1.2	90
236	Mutation analysis of papillary tubal hyperplasia associated with ovarian atypical proliferative serous tumor and low-grade serous carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, e6-e8.	0.7	5
237	Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. <i>International Journal of Cancer</i> , 2013, 133, 730-739.	2.3	18
238	Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. <i>Cancer Cell</i> , 2013, 24, 751-765.	7.7	488
239	Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 170, 251-254.	0.5	35
240	Tu-be or not tu-be: That is the question! About serous ovarian carcinogenesis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 134-143.	2.0	46
241	Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. <i>Gynecologic Oncology</i> , 2013, 129, 120-123.	0.6	13
242	Secretory cell expansion with aging: Risk for pelvic serous carcinogenesis. <i>Gynecologic Oncology</i> , 2013, 131, 555-560.	0.6	26
243	Hereditary gynaecological malignancies: advances in screening and treatment. <i>Histopathology</i> , 2013, 62, 2-30.	1.6	43
244	Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. <i>Histopathology</i> , 2013, 62, 59-70.	1.6	90
245	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. <i>Histopathology</i> , 2013, 62, 44-58.	1.6	238
246	Surgical Implications of the Potential New Tubal Pathway for Ovarian Carcinogenesis. <i>Journal of Minimally Invasive Gynecology</i> , 2013, 20, 153-159.	0.3	46
247	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. <i>Cancer Treatment Reviews</i> , 2013, 39, 561-568.	3.4	24

#	ARTICLE	IF	CITATIONS
248	Proteomic analyses of serous and endometrioid epithelial ovarian cancers â€“ Cases studies â€“ Molecular insights of a possible histological etiology of serous ovarian cancer. <i>Proteomics - Clinical Applications</i> , 2013, 7, 337-354.	0.8	18
249	Support of the â€˜fallopian tube hypothesisâ€™™ in a prospective series of risk-reducing salpingo-oophorectomy specimens. <i>European Journal of Cancer</i> , 2013, 49, 132-141.	1.3	95
250	Alternatives to risk-reducing surgery for ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, viii47-viii53.	0.6	15
251	Through the glass darkly: intraepithelial neoplasia, topâ€ˆdown differentiation, and the road to ovarian cancer. <i>Journal of Pathology</i> , 2013, 231, 402-412.	2.1	68
252	Imaging of primary fallopian tube carcinoma. <i>Abdominal Imaging</i> , 2013, 38, 608-618.	2.0	20
253	High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy. <i>Case Reports in Oncology</i> , 2013, 6, 21-24.	0.3	1
254	Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer. <i>Future Oncology</i> , 2013, 9, 1257-1261.	1.1	3
255	Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. <i>Modern Pathology</i> , 2013, 26, 572-578.	2.9	22
256	Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977â€“2010. <i>BMJ Open</i> , 2013, 3, e002845.	0.8	19
257	New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. <i>BioMed Research International</i> , 2013, 2013, 1-13.	0.9	22
258	Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 529-535.	0.9	34
259	Fallopian Tube Intraluminal Tumor Spread From Noninvasive Precursor Lesions. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1123-1130.	2.1	55
260	Serous Tubal In Situ Carcinoma (STIC) in Primary Peritoneal Serous Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 339-344.	0.9	27
261	Precursor Lesions and Prognostic Factors in Primary Peritoneal Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 547-555.	0.9	16
262	Do Deeper Sections Increase the Frequency of Detection of Serous Tubal Intraepithelial Carcinoma (STIC) in the â€œSectioning and Extensively Examining the Fimbriated Endâ€•(SEE-FIM) Protocol?. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 353-357.	0.9	37
263	Ovarian Carcinosarcoma Associated With Bilateral Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 384-389.	0.9	12
264	Evidence of a Chemopreventive Effect of Progesterin Unrelated to Ovulation on Reproductive Tract Cancers in the Egg-laying Hen. <i>Cancer Prevention Research</i> , 2013, 6, 1283-1292.	0.7	14
265	Precursors and pathogenesis of ovarian carcinoma. <i>Pathology</i> , 2013, 45, 229-242.	0.3	128

#	ARTICLE	IF	CITATIONS
266	Abdominopelvic washings: A comprehensive review. <i>CytoJournal</i> , 2013, 10, 7.	0.8	32
267	Correlation of Cellular Patterns in Proliferative Epithelial Lesions of the Uterine Tube with Lesions in the Ovary: A Histopathologic Study. <i>Journal of Gynecologic Surgery</i> , 2013, 29, 179-185.	0.0	0
268	Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. <i>British Journal of Cancer</i> , 2013, 109, 603-609.	2.9	42
269	Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. <i>Human Reproduction</i> , 2013, 28, 1406-1417.	0.4	92
270	Risk-Reducing Salpingectomy as Preventative Strategy for Pelvic Serous Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 417-421.	1.2	37
271	Clinicopathologic Analysis of Low-stage Sporadic Ovarian Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 356-367.	2.1	14
272	Ovarian Cancer Biomarker Discovery Based on Genomic Approaches. <i>Journal of Cancer Prevention</i> , 2013, 18, 298-312.	0.8	19
273	Cytologic Findings in Experimental in vivo Fallopian Tube Brush Specimens. <i>Acta Cytologica</i> , 2013, 57, 611-618.	0.7	16
274	FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 350-354.	0.8	2
275	Fallopian tube tumors: an overview. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2013, , .	0.1	0
276	Fallopian Tube Prolapse after Hysterectomy: A Systematic Review. <i>PLoS ONE</i> , 2013, 8, e76543.	1.1	24
277	Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. <i>PLoS ONE</i> , 2013, 8, e80314.	1.1	43
278	Avian WNT4 in the Female Reproductive Tracts: Potential Role of Oviduct Development and Ovarian Carcinogenesis. <i>PLoS ONE</i> , 2013, 8, e65935.	1.1	14
279	The origin of ovarian cancers - hypotheses and controversies. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 709-719.	0.8	55
280	Early detection of ovarian cancer. , 0, , 355-380.		0
281	Laparoscopic evaluation and management of adnexal masses and ovarian cancer. , 0, , 381-404.		0
282	Peritoneal and tubal serous carcinoma. , 0, , 111-120.		0
283	Ovarian Cancer Recurrence: Role of Ovarian Stem Cells and Epithelial-to-Mesenchymal Transition. <i>Journal of Cancer Science & Therapy</i> , 2014, 06, .	1.7	1

#	ARTICLE	IF	CITATIONS
284	Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management. International Journal of Women's Health, 2014, 6, 149.	1.1	4
285	Ovarian Carcinogenesis. , 2014, , 1356-1374.		0
286	Glucocorticoid-Induced Reversal of Interleukin-1 β -Stimulated Inflammatory Gene Expression in Human Oviductal Cells. PLoS ONE, 2014, 9, e97997.	1.1	9
287	MUC1 Positive, Kras and Pten Driven Mouse Gynecologic Tumors Replicate Human Tumors and Vary in Survival and Nuclear Grade Based on Anatomical Location. PLoS ONE, 2014, 9, e102409.	1.1	12
288	Adult Stem Cell Niches " Stem Cells in the Female Reproductive System. , 2014, , .		2
289	Epithelial ovarian cancer: An overview. World Journal of Translational Medicine, 2014, 3, 1.	3.5	109
290	The <sc>PAX2</sc> null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. Journal of Pathology, 2014, 234, 478-487.	2.1	30
291	FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene, 2014, 33, 4424-4432.	2.6	29
293	Pathology of the Ovary, Fallopian Tube and Peritoneum. , 2014, , .		3
294	Primary Fallopian Tube Carcinoma Arising in the Setting of Chronic Pelvic Inflammatory Disease. Case Reports in Medicine, 2014, 2014, 1-7.	0.3	5
295	Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?. Frontiers in Genetics, 2014, 5, 151.	1.1	9
296	Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. BioMed Research International, 2014, 2014, 1-11.	0.9	164
297	Prophylactic Bilateral Salpingectomy as a Prevention Strategy in Women at High-Risk of Ovarian Cancer: A Mini-Review. Frontiers in Oncology, 2014, 4, 21.	1.3	29
298	Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer. Frontiers in Oncology, 2014, 4, 322.	1.3	14
299	The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 133-140.	0.3	70
300	The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type. Annals of Oncology, 2014, 25, 1255-1258.	0.6	15
301	Risk—reducing surgery for women at high risk of epithelial ovarian cancer. The Obstetrician and Gynaecologist, 2014, 16, 185-191.	0.2	7
302	Pelvic Inflammation and the Pathogenesis of Ovarian Cancer: A Cohort Study. International Journal of Gynecological Cancer, 2014, 24, 1406-1413.	1.2	15

#	ARTICLE	IF	CITATIONS
303	Ovarian Cancer Rates After Hysterectomy With and Without Salpingo-Oophorectomy. <i>Obstetrics and Gynecology</i> , 2014, 123, 65-72.	1.2	27
304	Evaluation of the Fallopian Tubes After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 463-469.	0.9	11
305	Early Preinvasive Lesions in Ovarian Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	18
306	High Prevalence of Atypical Hyperplasia in the Endometrium of Patients With Epithelial Ovarian Cancer. <i>American Journal of Clinical Pathology</i> , 2014, 142, 213-221.	0.4	7
307	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	1.2	44
308	Characterization of the Immune Cell Repertoire in the Normal Fallopian Tube. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 581-591.	0.9	46
309	Quantitative Analysis of γ -H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 309-316.	0.9	8
310	Epigenetic biomarkers in epithelial ovarian cancer. <i>Cancer Letters</i> , 2014, 342, 257-263.	3.2	76
311	Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 1079-1085.	0.8	2
312	Ovarian cancer screening—Current status, future directions. <i>Gynecologic Oncology</i> , 2014, 132, 490-495.	0.6	115
313	Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 859-865.	1.2	71
314	Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. <i>BMC Cancer</i> , 2014, 14, 80.	1.1	102
315	Serous borderline tumor of the fallopian tube in an adolescent: case report and review of the literature. <i>International Cancer Conference Journal</i> , 2014, 3, 227-231.	0.2	0
316	Altered expression of inflammation-associated genes in oviductal cells following follicular fluid exposure: Implications for ovarian carcinogenesis. <i>Experimental Biology and Medicine</i> , 2014, 239, 24-32.	1.1	38
317	Cell surface protein glycosylation in cancer. <i>Proteomics</i> , 2014, 14, 525-546.	1.3	436
318	Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1383-1393.	1.1	23
319	Pivotal roles for hormonally regulated expression of the HEP21 gene in the reproductive tract of chickens for oviduct development and in ovarian carcinogenesis. <i>Domestic Animal Endocrinology</i> , 2014, 48, 136-144.	0.8	6
320	A mouse model for endometrioid ovarian cancer arising from the distal oviduct. <i>International Journal of Cancer</i> , 2014, 135, 1028-1037.	2.3	24

#	ARTICLE	IF	CITATIONS
321	A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. <i>Journal of Pathology</i> , 2014, 233, 228-237.	2.1	112
322	Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 241-246.	0.8	39
323	Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 27-45.	9.6	142
324	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 471.e1-471.e11.	0.7	236
325	Staging classification for cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 124, 1-5.	1.0	1,010
326	Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development: "When sweet turns sour". <i>Gynecologic Oncology</i> , 2014, 135, 371-381.	0.6	27
327	Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 423-427.	0.6	97
328	Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol. <i>Modern Pathology</i> , 2014, 27, 1002-1013.	2.9	38
329	Three-dimensional modeling of ovarian cancer. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 184-192.	6.6	35
330	Ovarian borderline tumours: a review with comparison of serous and mucinous types. <i>Diagnostic Histopathology</i> , 2014, 20, 333-350.	0.2	8
331	Clasificación histopatológica de los tumores ováricos. <i>EMC - Ginecología-Obstetricia</i> , 2014, 50, 1-24.	0.0	0
332	A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2014, 134, 492-497.	0.6	24
334	The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer. <i>Gynecologic Oncology</i> , 2014, 134, 486-491.	0.6	12
336	Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers. <i>Cancer Research</i> , 2014, 74, 1141-1152.	0.4	151
337	Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. <i>Histopathology</i> , 2014, 65, 149-154.	1.6	69
338	Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 193-213.	6.6	45
339	Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas. <i>American Journal of Pathology</i> , 2014, 184, 1871-1876.	1.9	2
340	Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2014, 132, 280-286.	0.6	74

#	ARTICLE	IF	CITATIONS
341	2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014, 133, 401-404.	0.6	251
342	Ovarian cancer. <i>Lancet, The</i> , 2014, 384, 1376-1388.	6.3	1,491
343	Pathogenesis and Role of Serous Tubal Intraepithelial Carcinoma in the Development of Ovarian Cancers. <i>Postgraduate Obstetrics & Gynecology</i> , 2014, 34, 1-5.	0.1	0
344	Pathogenesis and Role of Serous Tubal Intraepithelial Carcinoma in the Development of Ovarian Cancers. <i>Postgraduate Obstetrics & Gynecology</i> , 2014, 34, 6.	0.1	0
346	Tubal Ligation Induces Quiescence in the Epithelia of the Fallopian Tube Fimbria. <i>Reproductive Sciences</i> , 2015, 22, 1262-1271.	1.1	7
347	Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 1.	3.6	27
349	Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum. <i>Obstetrics and Gynecology</i> , 2015, 126, 171-174.	1.2	87
350	Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1201-1207.	1.2	13
351	Mutant p53 expression in fallopian tube epithelium drives cell migration. <i>International Journal of Cancer</i> , 2015, 137, 1528-1538.	2.3	38
352	Serous Tubal Intraepithelial Carcinoma (STIC)-like Lesions Arising in Ovarian Serous Cystadenofibroma. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 535-540.	0.9	8
353	Opportunistic bilateral salpingectomy during gynaecological surgery for benign disease: A survey of current <scp>A</scp>ustralian and New Zealand practice. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015, 55, 606-611.	0.4	20
354	Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum. <i>Cancer</i> , 2015, 121, 3452-3454.	2.0	61
355	Committee Opinion No. 620. <i>Obstetrics and Gynecology</i> , 2015, 125, 279-281.	1.2	169
356	DNA Damage Signaling and Apoptosis in Preinvasive Tubal Lesions of Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 761-769.	1.2	14
357	Salpingectomy for Sterilization. <i>Postgraduate Obstetrics & Gynecology</i> , 2015, 35, 1-5.	0.1	0
358	Management of cancer of the ovary. , 0, , 345-359.		0
359	C�ncer seroso papilar de alto grado: evidencia sobre su origen en la trompa de Falopio. <i>Revista Chilena De Obstetricia Y Ginecologia</i> , 2015, 80, 414-420.	0.1	0
360	FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 87.	1.0	238

#	ARTICLE	IF	CITATIONS
361	Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 149.	1.3	52
362	RelA-Induced Interferon Response Negatively Regulates Proliferation. <i>PLoS ONE</i> , 2015, 10, e0140243.	1.1	16
363	Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer. <i>AMA Journal of Ethics</i> , 2015, 17, 843-848.	0.4	5
364	Serous Tubal Intraepithelial Carcinoma: An Incidental Finding at the Time of Prophylactic Bilateral Salpingo-Oophorectomy. <i>Case Reports in Obstetrics and Gynecology</i> , 2015, 2015, 1-4.	0.2	6
365	Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy. <i>Obstetrics and Gynecology</i> , 2015, 125, 338-345.	1.2	106
366	FIGO 2013 staging system for ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 48-52.	0.9	24
367	Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases. <i>American Journal of Surgical Pathology</i> , 2015, 39, 357-364.	2.1	104
368	Evidence for a Dualistic Model of High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 287-293.	2.1	96
369	A 16-week secondary abdominal ectopic pregnancy with a simultaneous intratubal placenta and abdominal fetus. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 185, 181-182.	0.5	2
370	Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 231-234.	0.8	33
371	The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 39-54.	1.2	55
372	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. <i>Clinical Cancer Research</i> , 2015, 21, 4960-4969.	3.2	62
373	Salpingectomy as a Means to Reduce Ovarian Cancer Risk. <i>Cancer Prevention Research</i> , 2015, 8, 342-348.	0.7	54
374	The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. <i>Pathology</i> , 2015, 47, 423-431.	0.3	48
375	Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 86-94.	1.3	159
376	The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. <i>Gynecologic Oncology</i> , 2015, 136, 205-211.	0.6	30
378	Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: Patients' and professionals' perspectives. <i>Gynecologic Oncology</i> , 2015, 136, 305-310.	0.6	31
379	Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities? A systematic review. <i>Gynecologic Oncology</i> , 2015, 136, 571-581.	0.6	27

#	ARTICLE	IF	CITATIONS
380	Precursors of ovarian cancer in the fallopian tube: <scp>S</scp>erous tubal intraepithelial carcinoma “an update. Journal of Obstetrics and Gynaecology Research, 2015, 41, 6-11.	0.6	34
381	Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology, 2015, 67, 331-337.	1.6	39
383	Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 188, 133-135.	0.5	7
384	The domestic chicken: Causes and consequences of an egg a day. Poultry Science, 2015, 94, 816-820.	1.5	45
385	Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2015, 107, dju410-dju410.	3.0	300
386	Next-Generation Sequencing of Tubal Intraepithelial Carcinomas. JAMA Oncology, 2015, 1, 1128.	3.4	101
387	PAX8 expression in ovarian surface epithelial cells. Human Pathology, 2015, 46, 948-956.	1.1	36
389	Diethylstilbestrol regulates expression of avian apolipoprotein D during regression and recrudescence of the oviduct and epithelial-derived ovarian carcinogenesis. Domestic Animal Endocrinology, 2015, 52, 82-89.	0.8	5
390	Low rates of fimbrial excision at tubal ligation: room for improvement?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 185, 182-183.	0.5	0
391	Peritoneal carcinomatosis: A malignant disease with an embryological origin?. Surgical Oncology, 2015, 24, 305-311.	0.8	6
392	<i>TP53</i> mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Research, 2015, 43, 6945-6958.	6.5	46
393	Other Primary Peritoneal Surface Malignancies. Updates in Surgery Series, 2015, , 329-338.	0.0	0
395	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern Pathology, 2015, 28, 1101-1122.	2.9	164
396	Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes and Control, 2015, 26, 601-608.	0.8	4
397	Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. Expert Opinion on Investigational Drugs, 2015, 24, 345-362.	1.9	1
398	Ovarian cancer risk reduction through opportunistic salpingectomy. Journal of Gynecologic Oncology, 2015, 26, 83.	1.0	13
399	Proteomics of ovarian cancer: functional insights and clinical applications. Cancer and Metastasis Reviews, 2015, 34, 83-96.	2.7	55
400	Fimbrial Cells Exposure to Catalytic Iron Mimics Carcinogenic Changes. International Journal of Gynecological Cancer, 2015, 25, 389-398.	1.2	23

#	ARTICLE	IF	CITATIONS
401	Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. <i>Cancer</i> , 2015, 121, 2108-2120.	2.0	202
402	Incidence of Serous Tubal Intraepithelial Carcinoma (STIC) by Algorithm Classification in Serous Ovarian Tumor Associated with PAX8 Expression in Tubal Epithelia. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 9-18.	0.9	12
403	Characterization of Precursor Lesions in the Endometrium and Fallopian Tube Epithelium of Early-Stage Uterine Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 57-64.	0.9	37
404	Incidental Serous Tubal Intraepithelial Carcinoma and Early Invasive Serous Carcinoma in the Nonprophylactic Setting. <i>American Journal of Surgical Pathology</i> , 2015, 39, 442-453.	2.1	71
405	Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 858-869.	1.4	39
406	New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 262-267.	0.7	124
407	Should Fallopian Tubes Be Removed During Hysterectomy Procedures? – A Statement by AGO Ovar. Geburtshilfe Und Frauenheilkunde, 2015, 75, 339-341.	0.8	11
408	Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. <i>Gynecologic Oncology</i> , 2015, 139, 236-241.	0.6	70
409	The role of reproductive hormones in epithelial ovarian carcinogenesis. <i>Endocrine-Related Cancer</i> , 2015, 22, R339-R363.	1.6	33
410	Opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 5.	3.6	28
411	Round Ligament Technique and Use of a Vessel-sealing Device to Facilitate Complete Salpingectomy at the Time of Vaginal Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 1084-1087.	0.3	10
412	National trends of adnexal surgeries at the time of hysterectomy for benign indication, United States, 1998–2011. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 713.e1-713.e13.	0.7	54
413	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S111-22.	1.0	70
414	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
415	Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor. <i>Human Pathology</i> , 2015, 46, 1455-1463.	1.1	12
416	Mutagenic, surviving and tumorigenic effects of follicular fluid in the context of p53 loss: initiation of fimbria carcinogenesis. <i>Carcinogenesis</i> , 2015, 36, 1419-1428.	1.3	65
417	The Ovary Is an Alternative Site of Origin for High-Grade Serous Ovarian Cancer in Mice. <i>Endocrinology</i> , 2015, 156, 1975-1981.	1.4	65
418	Ovary and fimbrial stem cells: biology, niche and cancer origins. <i>Nature Reviews Molecular Cell Biology</i> , 2015, 16, 625-638.	16.1	80

#	ARTICLE	IF	CITATIONS
419	Molecular Pathogenesis of Ovarian Cancer. , 2015, , 531-548.e2.		2
420	Early salpingectomy (Tubectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 2015, 15, 593.	1.1	88
421	Human Oviduct and Endometrium. , 2015, , 1077-1097.		6
422	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Modern Pathology, 2015, 28, 437-445.	2.9	16
423	Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Modern Pathology, 2015, 28, 118-127.	2.9	29
424	Genomic Applications in Pathology. , 2015, , .		1
425	Telomeres and Genomic Instability from Precancerous Lesions to Advanced Cancer – Understanding Through Ovarian Cancer. , 0, , .		0
426	Genetic and molecular changes in ovarian cancer. Cancer Biology and Medicine, 2016, 13, 236-247.	1.4	82
427	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. Current Cancer Therapy Reviews, 2016, 12, 23-36.	0.2	0
428	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e247-e257.	1.8	9
429	Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. Case Reports in Pathology, 2016, 2016, 1-5.	0.2	3
430	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Frontiers in Oncology, 2016, 6, 119.	1.3	15
431	Platelet-Derived Growth Factor in the Ovarian Follicle Attracts the Stromal Cells of the Fallopian Tube Fimbriae. PLoS ONE, 2016, 11, e0158266.	1.1	7
432	Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma. International Journal of Gynecological Pathology, 2016, 35, 230-237.	0.9	44
433	<i>In vitro</i> and <i>in vivo</i> correlates of physiological and neoplastic human Fallopian tube stem cells. Journal of Pathology, 2016, 238, 519-530.	2.1	68
434	The Origin of Epithelial Neoplasms of the Ovary. Advances in Anatomic Pathology, 2016, 23, 50-57.	2.4	6
435	Culprit or Bystander? The Role of the Fallopian Tube in –Ovarian–High-Grade Serous Carcinoma. Cancer Discovery, 2016, 6, 1309-1311.	7.7	2
436	Probability of Fallopian Tube and Ovarian Detection with Transvaginal Ultrasonography in Normal Women. Women's Health, 2016, 12, 303-311.	0.7	12

#	ARTICLE	IF	CITATIONS
437	Small RNA sequencing reveals a comprehensive miRNA signature of <i>BRCA1</i> -associated high-grade serous ovarian cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 979-985.	1.0	11
438	Salpingectomy and prevention of ovarian carcinoma. <i>Gynecology and Minimally Invasive Therapy</i> , 2016, 5, 102-105.	0.2	0
440	Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. <i>American Journal of Roentgenology</i> , 2016, 206, 1351-1360.	1.0	130
441	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic <i>TP53</i> mutations in noncancerous tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6005-6010.	3.3	135
442	TNF- α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?. <i>Human Pathology</i> , 2016, 54, 82-91.	1.1	45
443	Adnexal masses requiring reoperation in women with previous hysterectomy with or without adnexectomy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 200, 123-127.	0.5	6
444	Abdominopelvic washings in gynecologic pathology: A comprehensive review. <i>Diagnostic Cytopathology</i> , 2016, 44, 1039-1057.	0.5	11
445	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464.	0.6	17
446	Genetically defined ovarian cancer mouse models. <i>Journal of Pathology</i> , 2016, 238, 180-184.	2.1	20
447	CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Research</i> , 2016, 76, 6118-6129.	0.4	145
448	Trends of Bilateral Salpingectomy During Vaginal Hysterectomy With and Without Laparoscopic Assistance Performed for Benign Indications in the United States. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 1063-1069.e1.	0.3	10
449	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2016, 29, 1254-1261.	2.9	72
450	Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening. <i>Women's Health</i> , 2016, 12, 475-479.	0.7	9
451	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16061.	18.1	761
452	Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1311-1321.	1.1	25
453	Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. <i>Nature Communications</i> , 2016, 7, 12645.	5.8	171
454	Experience With Opportunistic Salpingectomy in a Large, Community-Based Health System in the United States. <i>Obstetrics and Gynecology</i> , 2016, 128, 277-283.	1.2	49
455	Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingoophorectomy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1415-1420.	1.2	19

#	ARTICLE	IF	CITATIONS
456	Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers. <i>Surgical Pathology Clinics</i> , 2016, 9, 307-328.	0.7	3
457	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	0.7	7
458	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 48-55.	0.9	136
459	The fallopian tube as the origin of non-uterine pelvic high-grade serous carcinoma. <i>The Obstetrician and Gynaecologist</i> , 2016, 18, 143-152.	0.2	5
460	Precursors of High-Grade Serous Carcinoma. , 2016, , 3-22.		0
461	Letter to the Editor on "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" <i>Int J Gynecol Cancer</i> 2015;25. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 226-227.	1.2	4
462	Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 707-713.	1.4	10
463	The genetic prediction of risk for gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 141, 10-16.	0.6	41
464	Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. <i>International Journal of Cancer</i> , 2016, 138, 1076-1084.	2.3	49
465	The Dualistic Model of Ovarian Carcinogenesis. <i>American Journal of Pathology</i> , 2016, 186, 733-747.	1.9	717
466	Targeting the tumour microenvironment in ovarian cancer. <i>European Journal of Cancer</i> , 2016, 56, 131-143.	1.3	84
467	Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. <i>Gynecologic Oncology</i> , 2016, 141, 195-198.	0.6	60
468	Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. <i>Oncogene</i> , 2016, 35, 5010-5020.	2.6	23
470	Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. <i>Familial Cancer</i> , 2016, 15, 371-384.	0.9	4
471	It's Totally Tubular Riding The New Wave of Ovarian Cancer Research. <i>Cancer Research</i> , 2016, 76, 10-17.	0.4	105
472	YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. <i>Oncogene</i> , 2016, 35, 2247-2265.	2.6	63
474	The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets. <i>Seminars in Oncology</i> , 2016, 43, 189-197.	0.8	4
475	Hereditary Ovarian Cancer and Risk Reduction. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 31-48.	1.4	40

#	ARTICLE	IF	CITATIONS
476	Serous tubal intraepithelial neoplasia: the concept and its application. <i>Modern Pathology</i> , 2017, 30, 710-721.	2.9	77
477	Fallopian Tubes Take Center Stage with the Ovary. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 181.	0.3	0
478	Tubal origin of ovarian cancer – the double-edged sword of haemoglobin. <i>Journal of Pathology</i> , 2017, 242, 3-6.	2.1	18
479	Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis. <i>Modern Pathology</i> , 2017, 30, 563-576.	2.9	45
480	The Role of Opportunistic Bilateral Salpingectomy vs Tubal Occlusion or Ligation for Ovarian Cancer Prophylaxis. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 371-378.	0.3	28
481	Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid. <i>Gynecologic Oncology</i> , 2017, 145, 577-583.	0.6	10
482	Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 872-878.	1.1	57
483	Efficacy of salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 880-889.	1.1	22
485	Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 444-451.	1.2	18
486	Peripheral T-Cell Lymphoma Presenting as a Primary Uterine Cervix Mass: A Report of a Rare Case. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 523-527.	0.9	3
487	High-grade serous carcinoma of tubo-ovarian origin: recent developments. <i>Histopathology</i> , 2017, 71, 339-356.	1.6	71
488	Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. <i>Gynecologic Oncology</i> , 2017, 146, 69-73.	0.6	34
489	Ovarian cancer stem cells more questions than answers. <i>Seminars in Cancer Biology</i> , 2017, 44, 67-71.	4.3	128
490	Of mice and women - Non-ovarian origins of "ovarian" cancer. <i>Gynecologic Oncology</i> , 2017, 144, 5-7.	0.6	11
491	Unclassifiable Malignant Extraovarian Sex Cord-Stromal Tumors: Report of 3 Cases and Review of Extraovarian Sex Cord-Stromal Tumors. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 438-446.	0.9	14
492	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology</i> , 2017, 146, 373-379.	0.6	45
493	Pathogenesis and heterogeneity of ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 26-34.	0.9	223
494	L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 356-363.	0.9	7

#	ARTICLE	IF	CITATIONS
495	No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 480-493.	0.3	45
496	The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 230-239.	0.9	31
497	Malignant Brenner tumor associated with a germline BRCA2 mutation. <i>Gynecologic Oncology Reports</i> , 2017, 21, 17-19.	0.3	3
498	Persistence of fimbrial tissue on the ovarian surface after salpingectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 425.e1-425.e16.	0.7	27
499	High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease. <i>Journal of Pathology</i> , 2017, 243, 16-25.	2.1	90
500	Effective thermal destruction of residual tubal epithelium using an advanced sealing device in opportunistic salpingectomy: A randomized trial. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 108-112.	0.2	0
501	Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. <i>Oncologist</i> , 2017, 22, 450-459.	1.9	36
502	Risk-reducing salpingectomy: Let us be opportunistic. <i>Cancer</i> , 2017, 123, 1714-1720.	2.0	31
503	High-grade serous ovarian cancer 3 years after bilateral salpingectomy: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 201-203.	0.4	6
505	Transvaginal laparoscopy: A minimally invasive approach to obtain brush cytology of the Fallopian tube. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 212, 80-84.	0.5	3
506	Screening for Epithelial Ovarian Cancer: An Updated Review. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 1.	0.1	1
507	Role of Fallopian Tubes in the Development of Ovarian Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 230-234.	0.3	31
508	Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. <i>Cancer Letters</i> , 2017, 388, 158-166.	3.2	15
509	PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer. <i>Oncogene</i> , 2017, 36, 3015-3024.	2.6	14
510	Operative Outcomes of Opportunistic Bilateral Salpingectomy at the Time of Benign Hysterectomy in Low-Risk Premenopausal Women: A Systematic Review. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 218-229.	0.3	16
511	Salpingectomy for Sterilization. <i>Obstetrics and Gynecology</i> , 2017, 130, 961-967.	1.2	48
512	miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. <i>Human Pathology</i> , 2017, 70, 98-104.	1.1	14
513	Ovarian Cancer Prevention in High-risk Women. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 738-757.	0.6	25

#	ARTICLE	IF	CITATIONS
514	Cost-effectiveness of Ovarian Cancer Prevention Strategies. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 780-788.	0.6	4
516	Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. <i>Gynecologic Oncology</i> , 2017, 147, 634-641.	0.6	15
518	Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 686-696.	0.6	5
519	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. <i>Nature Communications</i> , 2017, 8, 990.	5.8	169
520	Taking the Tube: From Normal Fallopian Tube Epithelium to Ovarian High-grade Serous Carcinoma. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 697-710.	0.6	11
521	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , 2017, 8, 1093.	5.8	515
522	Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 37-56.	0.0	1
523	The Evolution of and Evidence for Opportunistic Salpingectomy. <i>Obstetrics and Gynecology</i> , 2017, 130, 814-824.	1.2	35
524	Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 1055-1062.	0.8	49
525	Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 493-506.	157.7	58
526	Feasibility of prophylactic salpingectomy during vaginal hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 605.e1-605.e5.	0.7	28
528	In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells. <i>Development (Cambridge)</i> , 2017, 144, 3031-3041.	1.2	71
529	Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. <i>Histopathology</i> , 2017, 71, 1014-1017.	1.6	6
530	BRCA mutation in ovarian cancer: testing, implications and treatment considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 519-531.	1.4	96
531	Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma. <i>Journal of Obstetrics and Gynecology of India</i> , 2017, 67, 432-441.	0.3	8
532	Risks and Benefits of Salpingectomy at the Time of Sterilization. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 663-668.	0.2	10
533	Hysterectomy with salpingectomy versus hysterectomy alone. <i>The Cochrane Library</i> , 2017, , .	1.5	1
534	Serous Tubal Intraepithelial Carcinoma or Not? Metastases to Fallopian Tube Mucosa Can Masquerade as In Situ Lesions. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1313-1315.	1.2	20

#	ARTICLE	IF	CITATIONS
535	Changes in the Extracellular Matrix Are Associated With the Development of Serous Tubal Intraepithelial Carcinoma Into High-Grade Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1072-1081.	1.2	11
536	Ovarian Epithelial Inclusions With Mucinous Differentiation. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 372-376.	0.9	10
537	Managing BRCA Mutation Carriers. , 2017, , .		0
538	Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. <i>BMC Cancer</i> , 2017, 17, 422.	1.1	12
539	LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions. <i>Modern Pathology</i> , 2017, 30, 1241-1250.	2.9	23
540	Granular Cell Tumor Within an Ovarian Mature Cystic Teratoma: Report of a Unique Case and Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 453-458.	0.9	2
541	Ovarian Cancers. , 2017, , .		1
542	Pathology and Molecular Pathology of Uterine and Ovarian Cancers. , 2017, , 247-278.		0
543	<i>TP53</i> Mutations in Breast and Ovarian Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026252.	2.9	116
544	Impact of opportunistic salpingectomy on anti- μ llerian hormone in patients undergoing laparoscopic hysterectomy: a multicentre randomised controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 314-320.	1.1	39
545	Pathology of borderline and invasive cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 15-30.	1.4	47
546	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. <i>Nature Reviews Cancer</i> , 2017, 17, 65-74.	12.8	235
547	Tubal contraception and ovarian cancer risk: a global view. <i>Contraception</i> , 2017, 95, 223-226.	0.8	5
548	Current Updates on Salpingectomy for the Prevention of Ovarian Cancer and Its Practice Patterns Worldwide. <i>Chinese Medical Sciences Journal</i> , 2017, 32, 185-192.	0.2	5
549	European/U.S. Comparison and Contrasts in Ovarian Cancer Screening and Prevention in a High-Risk Population. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 124-127.	1.8	3
550	Review of the literature on laparoscopic supracervical hysterectomy and related complications with single institution experience. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 0, , .	0.3	0
551	Cytokine Networks in the Ovary. , 2017, , 51-74.		1
552	Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer. <i>Cancers</i> , 2017, 9, 104.	1.7	73

#	ARTICLE	IF	CITATIONS
553	Origins of Epithelial Ovarian Cancer. , 2017, , 3-17.		2
554	Complications from Surgeries Related to Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 16.	1.3	5
555	Ovarian Cancer Incidence Corrected for Oophorectomy. <i>Diagnostics</i> , 2017, 7, 19.	1.3	10
556	A Residentâ€™s Perspective of Ovarian Cancer. <i>Diagnostics</i> , 2017, 7, 24.	1.3	11
557	Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials. <i>Diagnostics</i> , 2017, 7, 25.	1.3	3
558	A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come. <i>Diagnostics</i> , 2017, 7, 14.	1.3	72
559	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e54.	1.0	20
560	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2539-2551.	1.0	45
561	Epidemiology of ovarian cancer: a review. <i>Cancer Biology and Medicine</i> , 2017, 14, 9-32.	1.4	981
563	Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. <i>Endocrine-Related Cancer</i> , 2018, 25, R303-R318.	1.6	126
564	Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices. <i>Gynecologic Oncology</i> , 2018, 148, 515-520.	0.6	12
565	Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. <i>Tissue and Cell</i> , 2018, 52, 57-64.	1.0	5
566	Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. , 0, , 329-339.		0
567	PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation. <i>Oncogene</i> , 2018, 37, 1976-1990.	2.6	54
568	To oophorectomy or not to oophorectomy: Practice patterns among urologists treating bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 90.e1-90.e7.	0.8	7
569	Synchronous tumours of the female reproductive tract. <i>Pathology</i> , 2018, 50, 214-221.	0.3	24
570	Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 657-665.	1.2	7
571	Precancerous Lesions of Ovarian Cancerâ€™A US Perspective. <i>Journal of the National Cancer Institute</i> , 2018, 110, 692-693.	3.0	9

#	ARTICLE	IF	CITATIONS
572	Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries. <i>Journal of the National Cancer Institute</i> , 2018, 110, 750-757.	3.0	28
573	<i>Chlamydia trachomatis</i> , Chlamydial Heat Shock Protein 60 and Anti-Chlamydial Antibodies in Women with Epithelial Ovarian Tumors. <i>Translational Oncology</i> , 2018, 11, 546-551.	1.7	11
574	A Laparoendoscopic Single-site Surgical Approach to Laparoscopic Salpingectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 326-327.	0.3	3
575	Epithelial Ovarian Cancer. , 2018, , 253-289.e14.		3
576	Fallopian Tube Cancer. , 2018, , 314-319.e2.		1
577	Clear Cell Carcinoma of the Uterine Cervix Presented as a Submucosal Tumor Arising in a Background of Cervical Endometriosis. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 88-92.	0.9	15
578	Vulvar Carcinosarcoma Composed of Intestinal-type Mucinous Adenocarcinoma Associated With Anaplastic Pleomorphic and Spindle Cell Carcinoma and Heterologous Chondrosarcomatous and Osteosarcomatous Elements: A Case Report and Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 93-100.	0.9	7
579	Screening for ovarian cancer: imaging challenges and opportunities for improvement. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 293-303.	0.9	69
580	The Use of Opportunistic Salpingectomy at the Time of Benign Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 53-61.	0.3	12
581	Review of Sterilization Techniques and Clinical Updates. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1157-1164.	0.3	19
582	Ovarian Cancer: A Heterogeneous Disease. <i>Pathobiology</i> , 2018, 85, 41-49.	1.9	225
583	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 324-330.	0.9	13
584	Hysterectomy for the Transgendered Male: Review of Perioperative Considerations and Surgical Techniques with Description of a Novel 2-Port Laparoscopic Approach. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1149-1156.	0.3	11
585	Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial. <i>Maturitas</i> , 2018, 107, 1-6.	1.0	21
586	Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy. <i>Histopathology</i> , 2018, 72, 766-776.	1.6	13
587	Cancer Risk-Reducing Opportunities in Gynecologic Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1179-1193.	0.3	5
588	MRI findings for primary fallopian tube cancer: correlation with pathological findings. <i>Japanese Journal of Radiology</i> , 2018, 36, 134-141.	1.0	4
589	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. <i>Modern Pathology</i> , 2018, 31, 652-659.	2.9	12

#	ARTICLE	IF	CITATIONS
590	Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 101-109.	0.9	31
591	Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky061.	1.4	19
592	Metastatic Tumors of the Ovary. , 2018, , 1-73.		0
593	Expression of β -Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 363-370.	1.2	2
594	Characterization of Primary Cilia in Normal Fallopian Tube Epithelium and Serous Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1535-1544.	1.2	8
595	Ovarian Cancer Genetics: Subtypes and Risk Factors. , 0, , .		17
596	Changing Clinical Practice. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1101-1107.	1.2	6
597	Detection of tumor cells of serous tubal intraepithelial carcinoma (STIC) in cervical smears and rapid development of the ovarian involvement: A case report. <i>Diagnostic Cytopathology</i> , 2018, 46, 945-949.	0.5	5
598	Cell Origins of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018, 10, 433.	1.7	176
599	Frontiers in the Pathology and Pathogenesis of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 915-928.	0.9	12
600	Diseases of the Fallopian Tube and Paratubal Region. , 2018, , 1-66.		0
601	Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis. <i>Cancers</i> , 2018, 10, 468.	1.7	31
602	Bilateral salpingectomy to reduce the risk of ovarian/fallopian/peritoneal cancer in women at average risk: a position statement of the Korean Society of Obstetrics and Gynecology (KSOG). <i>Obstetrics and Gynecology Science</i> , 2018, 61, 542.	0.6	11
603	Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer. <i>Cancers</i> , 2018, 10, 337.	1.7	90
604	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018, 11, 697-706.	0.7	47
605	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.	1.0	205
606	Mesothelial to mesenchyme transition as a major developmental and pathological player in trunk organs and their cavities. <i>Communications Biology</i> , 2018, 1, 170.	2.0	50
607	Mesothelial cells facilitate cancer stem-like properties in spheroids of ovarian cancer cells. <i>Oncology Reports</i> , 2018, 40, 2105-2114.	1.2	21

#	ARTICLE	IF	CITATIONS
608	Tumor evolution and chemoresistance in ovarian cancer. <i>Npj Precision Oncology</i> , 2018, 2, 20.	2.3	106
609	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0
610	Comparison of the Classical Method and SEE-FIM Protocol in Detecting Microscopic Lesions in Fallopian Tubes with Gynecological Lesions. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 21-27.	0.4	29
611	Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2512.	1.8	30
612	The Fallopian Tube and Broad Ligament. , 2018, , 716-760.		1
613	Assessing Pelvic Epithelial Cancer Risk and Intercepting Early Malignancy. , 2018, , 844-864.		0
614	Metastatic Tumors Involving the Ovary. , 2018, , 1050-1069.		1
615	Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. <i>Human Pathology</i> , 2018, 80, 11-27.	1.1	170
616	Surgical prevention strategies in ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 166-175.	0.6	38
617	Alteration of microRNA profiling in sphere-cultured ovarian carcinoma cells. <i>Oncology Letters</i> , 2018, 16, 2016-2022.	0.8	1
618	Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 172.e1-172.e8.	0.7	27
619	Case for a role of the microbiome in gynecologic cancers: Clinician's perspective. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 1693-1704.	0.6	24
620	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 450.	1.8	13
621	Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. <i>Gynecologic Oncology</i> , 2018, 150, 79-84.	0.6	44
622	Inflammation is a key contributor to ovarian cancer cell seeding. <i>Scientific Reports</i> , 2018, 8, 12394.	1.6	58
623	UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018, 10, 262.	1.7	25
624	Organotypic 3D Models of the Ovarian Cancer Tumor Microenvironment. <i>Cancers</i> , 2018, 10, 265.	1.7	43
625	Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. <i>Cancer Medicine</i> , 2018, 7, 5047-5056.	1.3	44

#	ARTICLE	IF	CITATIONS
626	Algorithms Used in Ovarian Cancer Detection: A Minireview on Current and Future Applications. <i>Journal of applied laboratory medicine</i> , The, 2018, 3, 290-299.	0.6	3
627	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 16.	0.7	123
628	Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 794-798.	0.6	5
629	Origins based clinical and molecular complexities of epithelial ovarian cancer. <i>International Journal of Biological Macromolecules</i> , 2018, 118, 1326-1345.	3.6	21
630	Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer. , 2018, , 221-252.		0
631	Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery. <i>Obstetrics and Gynecology</i> , 2018, 132, 20-27.	1.2	46
632	Evaluation of SEE-FIM (Sectioning and Extensively Examining the FIMbriated End) Protocol in Identifying Fallopian Tube Precursor Lesions in Women with Ovarian Tumors. <i>Journal of Obstetrics and Gynecology of India</i> , 2019, 69, 153-159.	0.3	4
633	Fallopian Tube Neoplasia and Mimics. <i>Surgical Pathology Clinics</i> , 2019, 12, 457-479.	0.7	10
634	Ovarian High-Grade Serous Carcinoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 515-528.	0.7	7
635	Salpingectomy at the time of hysterectomy for benign gynaecological disease: A comparison of surgical approaches. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 725-729.	0.4	0
636	Fallopian Tube Carcinoma. <i>Journal of Oncology Practice</i> , 2019, 15, 375-382.	2.5	28
637	Novel Approaches to Ovarian Cancer Screening. <i>Current Oncology Reports</i> , 2019, 21, 75.	1.8	56
638	Secondary Tumors of the Ovary. , 2019, , 323-366.		3
639	Peritoneum and Broad Ligament. , 2019, , 367-403.		0
640	Fallopian Tube. , 2019, , 53-77.		0
641	Ovarian Epithelial Carcinogenesis. , 2019, , 121-139.		2
642	Serous Neoplasms of the Ovary. , 2019, , 141-171.		1
643	Diseases of the Fallopian Tube and Paratubal Region. , 2019, , 649-714.		3

#	ARTICLE	IF	CITATIONS
644	Metastatic Tumors of the Ovary. , 2019, , 1151-1222.		0
645	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. International Journal of Molecular Sciences, 2019, 20, 5129.	1.8	19
646	Defining fallopian tube-derived miRNA cancer signatures. Cancer Medicine, 2019, 8, 6709-6716.	1.3	7
647	Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression. Cancers, 2019, 11, 1513.	1.7	34
648	The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy. International Journal of Molecular Sciences, 2019, 20, 5482.	1.8	51
649	Completeness of salpingectomy intended for ovarian cancer risk reduction. Gynecologic Oncology, 2019, 155, 280-282.	0.6	4
651	Colon Metastasis From Microscopic Serous Carcinoma of the Fallopian Tube Fimbria Mimicking a Primary Colon Cancer. International Journal of Surgical Pathology, 2019, 27, 390-395.	0.4	6
652	Lineage tracing suggests that ovarian endosalpingiosis does not result from escape of oviductal epithelium. Journal of Pathology, 2019, 249, 206-214.	2.1	8
653	Challenges in Managing Patients with Hereditary Cancer at Gynecological Services. Obstetrics and Gynecology International, 2019, 2019, 1-9.	0.5	3
654	Prevention of Ovarian Cancer. , 2019, , 257-272.		0
655	Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. Cancer Prevention Research, 2019, 12, 401-412.	0.7	5
656	Effects of hysterectomy with simultaneous bilateral salpingectomy on the subsequent pelvic mass. Journal of Ovarian Research, 2019, 12, 27.	1.3	3
657	Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia. International Journal of Gynecological Pathology, 2019, 38, 443-448.	0.9	8
658	Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study. Journal of Oncology, 2019, 2019, 1-9.	0.6	10
659	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International Journal of Molecular Sciences, 2019, 20, 952.	1.8	381
660	Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report. Diagnostic Pathology, 2019, 14, 17.	0.9	4
661	No. 377-Hysterectomy for Benign Gynaecologic Indications. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 543-557.	0.3	28
662	Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review). Molecular and Clinical Oncology, 2019, 10, 323-330.	0.4	26

#	ARTICLE	IF	CITATIONS
663	Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. The Cochrane Library, 2019, 8, CD012858.	1.5	24
664	Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. Scientific Reports, 2019, 9, 19935.	1.6	26
665	Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma. Cancers, 2019, 11, 2008.	1.7	27
666	Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nature Communications, 2019, 10, 5367.	5.8	154
667	Complete salpingectomy versus tubal ligation during cesarean section: a systematic review and meta-analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3794-3802.	0.7	9
668	Ovarian Cancer Genetics and Implications for Imaging and Therapy. Journal of Computer Assisted Tomography, 2019, 43, 835-845.	0.5	11
669	No 377- Indications gynécologiques bâtonnignes de l'hystérectomie. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 558-574.	0.3	2
670	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. American Journal of Surgical Pathology, 2019, 43, 1083-1091.	2.1	15
671	ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. Obstetrics and Gynecology, 2019, 133, e279-e284.	1.2	85
672	A Comprehensive Review of Ovarian Serous Carcinoma. Advances in Anatomic Pathology, 2019, 26, 329-339.	2.4	40
673	Ovarian cancer stem cells and targeted therapy. Journal of Ovarian Research, 2019, 12, 120.	1.3	70
674	A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development. Cell Reports, 2019, 29, 3726-3735.e4.	2.9	39
675	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. American Journal of Pathology, 2019, 189, 513-520.	1.9	35
676	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Cancer Research, 2019, 79, 760-772.	0.4	38
677	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Journal of Pathology, 2019, 248, 41-50.	2.1	84
678	Genomic Applications in Ovarian Cancer. , 2019, , 471-482.		0
679	Postpartum salpingectomy: a procedure whose time has come. American Journal of Obstetrics and Gynecology, 2019, 220, 8-9.	0.7	1
680	The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers. Translational Research, 2019, 206, 71-90.	2.2	16

#	ARTICLE	IF	CITATIONS
681	The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. <i>Gynecologic Oncology</i> , 2019, 152, 127-132.	0.6	28
682	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
683	Sectioning and extensively examining the fimbriated end (SEEâ€FIM) of the fallopian tube in routine practices, is it worth the effort?. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 665-670.	0.6	8
684	Hysterectomy and opportunistic salpingectomy (HOPPSA): study protocol for a register-based randomized controlled trial. <i>Trials</i> , 2019, 20, 10.	0.7	11
685	Ovarian cancer in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27512.	0.8	17
686	The fallopian tube, â€œprecursor escapeâ€and narrowing the knowledge gap to the origins of high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 152, 426-433.	0.6	77
687	Survey of pelvic reconstructive surgeons on performance of opportunistic salpingectomy at the time of pelvic organ prolapse repair. <i>International Urogynecology Journal</i> , 2019, 30, 447-453.	0.7	5
688	Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 139-147.	0.5	9
689	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
690	Hysterectomy for the Transgender Man. , 2020, , 152-156.		0
691	Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 551-557.	0.4	2
692	Ovarian cancer screening in the general population. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	5
693	Feasibility and Outcomes of Opportunistic Bilateral Salpingectomy in Patients with Traditional Relative Contraindications to Vaginal Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 1405-1413.	0.3	2
694	An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 261-269.	0.9	7
695	Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts. <i>Cancer Research</i> , 2020, 80, 877-889.	0.4	15
696	Tubal cancer in a young woman camouflaged as bilateral salpingitis. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 1178-1180.	0.4	0
697	Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. <i>Modern Pathology</i> , 2020, 33, 29-37.	2.9	28
698	Evidence for a Novel Endometrioid Carcinogenic Sequence in the Fallopian Tube With Unique Beta-Catenin Expression. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 163-169.	0.9	6

#	ARTICLE	IF	CITATIONS
699	The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies. <i>Cancer Medicine</i> , 2020, 9, 421-431.	1.3	35
700	When Should Prophylactic Oophorectomy Be Recommended at the Time of Elective Hysterectomy?. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 337-348.	0.6	1
701	Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 401-406.	0.6	5
702	Clinicopathological and molecular analyses of linearly expanded epithelial cells with β -catenin alterations, "œœ"catenin signature" in the normal fallopian tube. <i>Histopathology</i> , 2020, 77, 880-889.	1.6	0
703	Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 94-99.	1.2	1
704	Pathology of Hereditary Breast and Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 531790.	1.3	30
705	Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation. <i>Cell Reports</i> , 2020, 32, 108086.	2.9	16
706	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. <i>Clinical Cancer Research</i> , 2020, 26, 6310-6320.	3.2	15
707	A Novel Role for NUAK1 in Promoting Ovarian Cancer Metastasis through Regulation of Fibronectin Production in Spheroids. <i>Cancers</i> , 2020, 12, 1250.	1.7	20
708	Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells. <i>Oncogenesis</i> , 2020, 9, 55.	2.1	8
709	Prevalence of endosalpingiosis and other benign gynecologic lesions. <i>PLoS ONE</i> , 2020, 15, e0232487.	1.1	17
710	Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. <i>Nature Communications</i> , 2020, 11, 2660.	5.8	75
711	HRness in Breast and Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3850.	1.8	14
712	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , 2020, 16, e1008808.	1.5	27
713	A comparative study of the turnover of multiciliated cells in the mouse trachea, oviduct, and brain. <i>Developmental Dynamics</i> , 2020, 249, 898-905.	0.8	11
714	miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. <i>Nature Communications</i> , 2020, 11, 3231.	5.8	24
715	Rationale for opportunistic salpingectomy during gynecological surgery for a benign condition: A review of the available literature. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2020, 49, 101829.	0.6	3
716	Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 779-785.	0.8	7

#	ARTICLE	IF	CITATIONS
717	Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention. <i>Familial Cancer</i> , 2020, 19, 143-151.	0.9	4
718	Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer. <i>The Cochrane Library</i> , 0, , .	1.5	3
719	Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications. <i>Cancer Letters</i> , 2020, 476, 152-160.	3.2	18
720	Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 221.e1-221.e11.	0.7	28
721	Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician. <i>Diagnostics</i> , 2020, 10, 102.	1.3	15
722	Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109974.	2.5	10
723	Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. <i>International Journal of Cancer</i> , 2020, 147, 1245-1251.	2.3	17
724	Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 611-615.	0.6	14
725	Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancersâ€”Stage Challenges Categorical Assignments of Indolence & Aggressiveness. <i>Diagnostics</i> , 2020, 10, 56.	1.3	11
726	Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampullaâ€”Site of Origin of Serous Carcinoma of the Ovary. <i>Cancers</i> , 2020, 12, 1090.	1.7	14
728	Targeting DNA Repair in Ovarian Cancer Treatment Resistance. <i>Clinical Oncology</i> , 2020, 32, 518-526.	0.6	18
729	The tubal epigenome â€” An emerging target for ovarian cancer. , 2020, 210, 107524.		10
730	The Origin of Ovarian Cancer Species and Precancerous Landscape. <i>American Journal of Pathology</i> , 2021, 191, 26-39.	1.9	102
731	Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 403-408.	0.3	9
732	Salpingectomy vs tubal ligation for sterilization: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 258-265.e4.	0.7	14
733	Prophylactic Surgery for Benign Gynecologic Pathologies. , 2021, , 313-324.		0
734	Hereditary Gynecological Malignancy and Molecular Features. <i>Current Human Cell Research and Applications</i> , 2021, , 145-165.	0.1	0
735	Tumores primarios de la trompa de Falopio. <i>EMC - GinecologÃa-Obstetricia</i> , 2021, 57, 1-10.	0.0	0

#	ARTICLE	IF	CITATIONS
736	Surgical Prevention in Ovarian Cancer. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 194-206.	0.1	0
737	Investigating the Molecular Carcinogenesis of Ovarian High-Grade Serous Carcinoma. <i>Current Human Cell Research and Applications</i> , 2021, , 41-56.	0.1	0
739	The organoid: A research model for ovarian cancer. <i>Tzu Chi Medical Journal</i> , 2022, 34, 255.	0.4	5
740	Models for measuring metabolic chemical changes in the metastasis of high grade serous ovarian cancer: fallopian tube, ovary, and omentum. <i>Molecular Omics</i> , 2021, 17, 819-832.	1.4	3
741	Ovulatory Follicular Fluid Facilitates the Full Transformation Process for the Development of High-Grade Serous Carcinoma. <i>Cancers</i> , 2021, 13, 468.	1.7	17
742	Miscellaneous Neoplasia of the Ovary. , 2021, , 283-295.		0
743	Transposable element regulation and expression in cancer. <i>FEBS Journal</i> , 2022, 289, 1160-1179.	2.2	60
744	Dual influence of TNF± on diverse in vitro models of ovarian cancer subtypes. <i>Heliyon</i> , 2021, 7, e06099.	1.4	3
745	Targeting the tumour microenvironment in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 3-28.	4.3	30
746	TGFÎ² signaling networks in ovarian cancer progression and plasticity. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 139-161.	1.7	31
747	Immunohistochemical Expression Status of p53, CD44v9, and Ki-67 in a Series of Fallopian Tube Lesions of High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 419-426.	0.9	4
748	Postpartum Salpingectomy Compared With Standard Tubal Ligation After Vaginal Delivery. <i>Obstetrics and Gynecology</i> , 2021, 137, 514-520.	1.2	8
749	Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 1699-1710.	2.9	21
750	Does the "Devil" originate from the fallopian tubes?. <i>Seminars in Cancer Biology</i> , 2021, 77, 56-66.	4.3	7
751	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	0.6	2
752	Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. <i>Cell Proliferation</i> , 2021, 54, e13029.	2.4	22
753	What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. <i>Diagnostics</i> , 2021, 11, 697.	1.3	57
754	The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. <i>Molecular Medicine</i> , 2021, 27, 33.	1.9	60

#	ARTICLE	IF	CITATIONS
755	BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art. <i>Cancers</i> , 2021, 13, 2562.	1.7	13
756	Transvaginal natural orifice transluminal endoscopic versus conventional vaginal hysterectomy with uterosacral ligament suspension for apical compartment prolapse. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 260, 203-207.	0.5	12
757	PRIMARY PERITONEAL SEROUS CARCINOMA- A RARE PRESENTATION & ITS DIAGNOSTIC CHALLENGES. , 2021, , 27-28.		0
758	FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3065.	1.7	37
759	MicroRNA characteristics in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252401.	1.1	4
760	Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids. <i>Journal of Pathology</i> , 2021, 255, 177-189.	2.1	6
761	Mutated p53 in HGSCâ€”From a Common Mutation to a Target for Therapy. <i>Cancers</i> , 2021, 13, 3465.	1.7	12
762	Risk of epithelial ovarian cancer <sc>Type I</sc> and <sc>II</sc> after hysterectomy, salpingectomy and tubal ligationâ€”A nationwide caseâ€”control study. <i>International Journal of Cancer</i> , 2021, 149, 1544-1552.	2.3	11
763	Long-term follow-up of 46 cases of primary fallopian tube carcinoma: a single institute study. <i>Annals of Palliative Medicine</i> , 2021, 10, 9122-9135.	0.5	2
764	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. <i>Gynecologic Oncology</i> , 2021, 163, 371-377.	0.6	2
765	Molecular Pathology of Ovarian Epithelial Neoplasms. <i>Surgical Pathology Clinics</i> , 2021, 14, 415-428.	0.7	2
766	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 5706-5719.	0.4	64
767	Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer. <i>Biochemical and Biophysical Research Communications</i> , 2021, 570, 74-81.	1.0	10
768	Barriers to salpingectomy for permanent contraception: A qualitative study with obstetricians and gynaecologists. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, 973-977.	0.4	0
769	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
770	Promising agents on the horizon. , 2021, , 151-164.		0
771	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. <i>Diagnostics</i> , 2021, 11, 199.	1.3	24
772	A unique case of splenic tumor exhibiting a serous carcinoma phenotype. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110169.	0.2	0

#	ARTICLE	IF	CITATIONS
773	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	2.3	498
774	Diseases of the Fallopian Tube and Paratubal Region. , 2011, , 529-578.		16
775	Metastatic Tumors of the Ovary. , 2011, , 929-997.		6
776	Molecular Pathology of Ovarian Cancer. , 2013, , 129-149.		1
777	Chemoresistance, Dormancy and Recurrence in Platinum Drug Therapy of Ovarian Cancers. , 2014, , 79-97.		1
778	Current Concept of Precancerous and Early Stage of Serous Ovarian Carcinoma. , 2018, , 37-46.		1
779	Biomarkers in the Management of Peritoneal Metastases. , 2020, , 251-279.		2
780	The peritoneum. , 2009, , 909-943.		2
781	Metastatic Tumors of the Ovary. , 2011, , 972-988.		3
782	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecologic disease in the United States. American Journal of Obstetrics and Gynecology, 2020, 223, 721.e1-721.e18.	0.7	28
783	Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20Âyears. Gynecologic Oncology, 2020, 159, 214-220.	0.6	2
784	Biopsie optique en gynÃ©cologie : lâ€™aspect pathologie anatomique. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 605-612.	0.0	2
785	Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer. Biochemical Society Transactions, 2020, 48, 2317-2333.	1.6	11
789	A comparison of p53 and <sc>WT</sc> 1 immunohistochemical expression patterns in tuboovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology, 2017, 71, 736-742.	1.6	27
790	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight, 2016, 1, .	2.3	45
791	Magnetic Resonance Imaging (MRI) and Three-Dimensional Transvaginal Ultrasonography Scanning for Preoperative Assessment of High Risk in Women with Endometrial Cancer. Medical Science Monitor, 2019, 25, 2024-2031.	0.5	26
792	Conditional Inactivation of p53 in Mouse Ovarian Surface Epithelium Does Not Alter MIS Driven Smad2-Dominant Negative Epithelium-Lined Inclusion Cysts or Teratomas. PLoS ONE, 2013, 8, e65067.	1.1	18
793	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. PLoS ONE, 2014, 9, e107643.	1.1	17

#	ARTICLE	IF	CITATIONS
794	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e247-e257.	1.8	8
795	How to manage BRCA mutation carriers?. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	6
796	Discovery of Prognostic Factors for Diagnosis and Treatment of Epithelial-Derived Ovarian Cancer from Laying Hens. Journal of Cancer Prevention, 2013, 18, 209-220.	0.8	13
797	Morphological basics of ovarian tumor histogenesis. Opuholi Zenskoj Reproaktivnoy Sistem, 2020, 16, 78-84.	0.1	1
798	Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer. Oncotarget, 2016, 7, 71123-71135.	0.8	32
799	PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget, 2017, 8, 76881-76897.	0.8	32
800	Reconstitution of high-grade serous ovarian carcinoma from primary fallopian tube secretory epithelial cells. Oncotarget, 2018, 9, 12609-12619.	0.8	23
801	Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget, 2018, 9, 22832-22849.	0.8	54
802	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. Annals of Translational Medicine, 2020, 8, 1709-1709.	0.7	7
803	Primitive Fallopian Tube Carcinosarcoma: Three Cases with Immunohistochemical Profiling. International Journal of Cancer and Clinical Research, 2015, 2, .	0.1	2
804	Pathology of BRCA-Associated Ovarian Cancers, Including Occult Cancers. , 2008, , 29-43.		2
805	Evaluating the progenitor cells of ovarian cancer: analysis of current animal models. BMB Reports, 2011, 44, 435-445.	1.1	24
806	The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer. , 0, , .		2
807	Fallopian tube adenocarcinoma in situ associated with adjuvant Tamoxifen therapy-A case report-. The Journal of the Japanese Society of Clinical Cytology, 2009, 48, 216-219.	0.0	1
808	Ovarian Cancer Update: Lessons From Morphology, Molecules, and Mice. Archives of Pathology and Laboratory Medicine, 2009, 133, 1775-1781.	1.2	61
809	Insights Into Selected Genetic Diseases Affecting the Female Reproductive Tract and Their Implication for Pathologic Evaluation of Gynecologic Specimens. Archives of Pathology and Laboratory Medicine, 2009, 133, 1041-1052.	1.2	8
810	Pseudoneoplastic Lesions of the Female Genital Tract. Archives of Pathology and Laboratory Medicine, 2010, 134, 393-403.	1.2	20
811	Origins and Pathology of Epithelial Ovarian Cancer: A Brief Overview. , 2021, , 1-17.		0

#	ARTICLE	IF	CITATIONS
812	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 61-85.	1.0	145
813	Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer. Biomedicines, 2021, 9, 1433.	1.4	13
815	Autofluorescence Imaging of Fallopian Tube Carcinogenesis. , 2010, , .		0
816	Gynecologic Tumors and Malignancies. , 2010, , 278-324.		1
817	The Fallopian Tube and Broad Ligament. , 2011, , 640-678.		1
819	Fallopian Tube and Peritoneum. , 2011, , 267-275.		1
821	Preventive Strategies in Epithelial Ovarian Cancer. , 0, , .		0
823	Pathology of Gynecologic Cancer. , 2013, , 21-38.		0
824	Epidemiology of Epithelial Ovarian Carcinoma. , 2013, , 3-12.		0
825	Tumoren und tumorartige Läsionen des Peritoneums. , 2013, , 923-966.		0
827	Ovarian Cancer in vitro Diagnostics: New Approaches to Earlier Detection. , 0, , .		0
828	Primary peritoneal serous papillary carcinoma (PSPC) involving ovary and colon: Management and Treatment. Journal of Cancer Research & Therapy, 2013, 1, 119-122.	0.1	0
830	Pathology of the Peritoneum. , 2014, , 431-463.		0
831	Noninvasive adenocarcinoma in the bilateral fallopian tubes occurring after tubal ligation. The Journal of the Japanese Society of Clinical Cytology, 2014, 53, 313-317.	0.0	0
832	Angio-Inhibitors in Ovarian Cancer. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
833	Specimen Cut-Up. , 2014, , 481-496.		1
835	Cancers Arising in the Ovary. , 2014, , 1592-1613.e6.		1
836	Pathology of the Fallopian Tube. , 2014, , 395-429.		0

#	ARTICLE	IF	CITATIONS
837	Novel Targeted Therapies for Patients with Ovarian Cancer. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
838	Genomic Applications in Epithelial Ovarian Malignancies. , 2015, , 489-502.		0
839	Ovarian and Adnexal Masses. , 2015, , 641-655.		0
840	Age of Salpingo-Oophorectomy and Risk of Peritoneal Carcinomatosis in Patients with a BRCA Mutation. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2015, 09, .	0.1	0
841	A novel outlook on preventive tubectomy. Russian Bulletin of Obstetrician-Gynecologist, 2015, 15, 48.	0.0	0
843	The Opportunistic Salpingectomy in Reducing Ovarian Cancer Risk: Do the Potential Benefits Outweigh Complications?. Surgical Research - Open Journal, 2016, 3, 20-23.	0.2	0
844	Title is missing!. , 2017, , .		4
845	Genetics of Ovarian Carcinomas. , 2017, , 13-31.		0
846	Fallopian tube pathology â€œ New findings: A review. Journal of Advanced Clinical and Research Insights, 2017, 4, 166-169.	0.1	0
847	A PROSPECTIVE OBSERVATIONAL STUDY OF THE CLINICOPATHOLOGICAL PROFILE, EPIDEMIOLOGICAL RISK FACTORS AND FALLOPIAN TUBE MUCOSAL INVOLVEMENT IN OVARIAN CANCER. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 18-23.	0.0	0
848	Prophylactic Oophorectomy for Patients with Germline BRCA Mutations. , 2017, , 65-87.		0
849	Pathology of Epithelial Ovarian Tumors. Comprehensive Gynecology and Obstetrics, 2017, , 83-113.	0.0	0
850	EVALUATION OF EFFECT OF BILATERAL TOTAL SALPINGECTOMY ON OVARIAN FUNCTION AMONG PRE-MENOPAUSAL WOMEN UNDERGOING ABDOMINAL HYSTERECTOMY. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 2833-2839.	0.1	0
851	Risk-reducing Salpingoâ€œOophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. Anticancer Research, 2017, 37, 5241-5248.	0.5	11
852	Traceback: leveraging archived biospecimens to identify mutation carriers. Oncotarget, 2017, 8, 90628-90629.	0.8	0
853	The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. Journal of Cancer Research and Therapeutics, 2018, 14, 587.	0.3	0
854	Ectopic Pregnancy: Laparoscopic Conservative Treatment and Laparoscopic Salpingotomy. World Journal of Laparoscopic Surgery, 2018, 11, 138-146.	0.2	0
855	A Case of Serous Tubal Intraepithelial Carcinoma Diagnosed by Cytology during the Operation. Open Journal of Pathology, 2018, 08, 69-77.	0.0	1

#	ARTICLE	IF	CITATIONS
856	Evaluation and Management of Adnexal Masses in Postmenopausal Women. <i>Current Women's Health Reviews</i> , 2018, 15, 41-45.	0.1	0
857	Cytology of the fallopian tube: A screening model for high-grade serous carcinoma. <i>CytoJournal</i> , 2018, 15, 28.	0.8	2
858	Expresi3n de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.. <i>Repertorio De Medicina Y Cirugia</i> , 2019, 28, .	0.0	0
859	Impact of bilateral total salpingectomy versus standard tubal ligation at time of cesarean section on ovarian reserve: A randomized controlled trial. , 2019, 9, 458-467.		3
862	Proportional vascularization along the fallopian tubes and ovarian fimbria: assessment by confocal microtomography. <i>Radiologia Brasileira</i> , 2020, 53, 161-166.	0.3	2
864	What we learn when our data are abnormal. , 2020, , 135-165.		0
865	Fallopian tube vascularization observed by microfocus computed tomography. <i>Radiologia Brasileira</i> , 2020, 53, 36-37.	0.3	2
866	Swyer Syndrome/46 XY Gonadal Dysgenesis: Remove the Tubes or Not?. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2021, 34, 771-772.	0.3	2
867	Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature. <i>Cureus</i> , 2020, 12, e9301.	0.2	1
868	Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. <i>World Journal of Clinical Oncology</i> , 2020, 11, 868-889.	0.9	17
870	An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 37-45.	0.5	12
871	Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 182-6.	0.5	11
872	Mucinous borderline tumor involving fallopian tube: case report and review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 962-5.	0.5	3
873	Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 848-57.	0.5	23
874	Tubal origin of ovarian low-grade serous carcinoma. <i>American Journal of Clinical and Experimental Obstetrics and Gynecology</i> , 2013, 1, 13-36.	0.5	3
875	Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2082-90.	0.0	12
876	Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 230-8.	0.0	0
877	IS "OVARIAN" CANCER A MISNOMER? EXPLORING OVARIAN CANCER ORIGINS IN THE MOUSE. <i>Transactions of the American Clinical and Climatological Association</i> , 2018, 129, 40-47.	0.9	1

#	ARTICLE	IF	CITATIONS
878	The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG). Facts, Views & Vision in ObGyn, 2019, 11, 177-187.	0.5	3
879	The HIPPO pathway in gynecological malignancies. American Journal of Cancer Research, 2020, 10, 610-629.	1.4	7
880	Identification of KIF23 as a prognostic signature for ovarian cancer based on large-scale sampling and clinical validation. American Journal of Translational Research (discontinued), 2020, 12, 4955-4976.	0.0	6
881	Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers, 2021, 13, 5908.	1.7	11
882	Prophylactic Bilateral Salpingo-oophorectomy. , 2021, , 499-502.		0
884	Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram. Diagnostics, 2022, 12, 144.	1.3	1
885	The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. Communications Biology, 2022, 5, 39.	2.0	11
887	Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium. Gynecologic Oncology, 2022, 165, 114-120.	0.6	6
888	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Network Open, 2022, 5, e2147343.	2.8	41
889	Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2. Cells, 2022, 11, 539.	1.8	17
890	Prophylactic bilateral salpingectomy: why is it worthwhile?. Medycyna Wieku Rozwojowego, 2018, 22, 390-395.	0.2	0
891	<i>TP53</i> variants in p53 signatures and the clonality of STICs in RRSO samples. Journal of Gynecologic Oncology, 2022, 33, .	1.0	7
892	Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecologic Oncology, 2022, 165, 568-576.	0.6	10
893	Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma. Frontiers in Oncology, 2022, 12, 853755.	1.3	5
894	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. Cells, 2021, 10, 3408.	1.8	4
895	Intra-Tumoral Nerve-Tracing in a Novel Syngeneic Model of High-Grade Serous Ovarian Carcinoma. Cells, 2021, 10, 3491.	1.8	10
896	A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. Genome Medicine, 2021, 13, 186.	3.6	12
897	Ageing accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma. Gynecologic Oncology, 2022, 165, 552-559.	0.6	4

#	ARTICLE	IF	CITATIONS
898	Ovary and fallopian tube. , 0, , 2726-2822.		0
899	Fallopian tube carcinoma. , 0, , 779-789.		0
901	Comparative analysis of peri-operative outcomes following total laparoscopic hysterectomy with conventional bipolar-electrosurgery versus high-pressure pulsed LigaSure use. Gynecology and Minimally Invasive Therapy, 2022, 11, 105.	0.2	4
902	The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination. Frontiers in Endocrinology, 2022, 13, 886533.	1.5	19
903	GBP5 and ACSS3: two potential biomarkers of high-grade ovarian cancer identified through downstream analysis of microarray data. Journal of Biomolecular Structure and Dynamics, 2023, 41, 4601-4613.	2.0	0
904	Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis. CMAJ Open, 2022, 10, E466-E475.	1.1	5
905	Three-dimensional transvaginal ultrasound vs magnetic resonance imaging for preoperative staging of deep myometrial and cervical invasion in patients with endometrial cancer: systematic review and meta-analysis. Ultrasound in Obstetrics and Gynecology, 2022, 60, 604-611.	0.9	12
906	Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstetrics and Gynecology, 2022, 139, 1196-1196.	1.2	0
907	Feasibility, Safety, and Provider Perspectives of Bipolar Electrosurgical Cautery Device for (Opportunistic or Complete) Salpingectomy at the Time of Cesarean Delivery. American Journal of Perinatology, 0, , .	0.6	0
908	Review of the literature on combined oral contraceptives and cancer. Ecancermedicalsecience, 0, 16, .	0.6	4
909	A randomized controlled trial of 2 techniques of salpingectomy during cesarean delivery. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100690.	1.3	1
910	<sc>Serous tubal intraepithelial carcinoma</sc>: what do we really know at this point?. Histopathology, 2022, 81, 542-555.	1.6	4
911	CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma. Cell Cycle, 0, , 1-15.	1.3	1
912	Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer. Genes and Diseases, 2023, 10, 1005-1018.	1.5	4
913	Salpingectomy, tubal ligation and hysteroscopic occlusion for sterilization. Minerva Obstetrics and Gynecology, 2022, 74, .	0.5	1
914	Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. Journal of Gynecologic Oncology, 2022, 33, .	1.0	4
915	The Toll-like Receptor 4 Polymorphism Asp299Gly Is Associated with an Increased Risk of Ovarian Cancer. Cells, 2022, 11, 3137.	1.8	7
916	Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis. Cancer Research, 2022, 82, 4528-4541.	0.4	9

#	ARTICLE	IF	CITATIONS
918	Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology, 2022, 41, S119-S142.	0.9	5
919	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
920	Molecular Management of High-Grade Serous Ovarian Carcinoma. International Journal of Molecular Sciences, 2022, 23, 13777.	1.8	6
921	Fallopian tube secreted protein affects ovarian metabolites in high grade serous ovarian cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
922	Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube. American Journal of Reproductive Immunology, 2023, 89, .	1.2	1
923	Theories regarding the origin and carcinogenesis of high-grade epithelial ovarian carcinoma and their clinical implications. Obstetrica Si Ginecologie, 2022, 3, 98.	0.0	0
924	Genomic Consequences of Ovarian Cancer with Respect to DNA Damage and Repair Mechanism. , 0, , .		0
925	Diagnostic value of circN4BP2L2 in type I and type II epithelial ovarian cancer. BMC Cancer, 2022, 22, .	1.1	1
926	UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: <i>RAD51C</i> , <i>RAD51D</i> , <i>BRIP1</i> and <i>PALB2</i> . Journal of Medical Genetics, 2023, 60, 417-429.	1.5	8
927	Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience. Diagnostics, 2022, 12, 3054.	1.3	0
928	Disparity in the era of personalized medicine for epithelial ovarian cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211480.	1.4	1
929	Serous Tumors of the Ovary. Encyclopedia of Pathology, 2023, , 1-12.	0.0	0
931	Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 2023, 62, 107-111.	0.5	3
932	Postpartum Opportunistic Salpingectomy Compared With Bilateral Tubal Ligation After Vaginal Delivery for Ovarian Cancer Risk Reduction. Obstetrics and Gynecology, 2023, 141, 819-827.	1.2	2
933	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
934	Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review. Cancers, 2023, 15, 711.	1.7	2
935	Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study. Cancers, 2023, 15, 1141.	1.7	6
936	Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. Journal of Clinical Medicine, 2023, 12, 1422.	1.0	4

#	ARTICLE	IF	CITATIONS
937	High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of <i>BRCA1/2</i> Pathogenic Variants: Prevalence and Clinical Factors. <i>Journal of Clinical Oncology</i> , 2023, 41, 2523-2535.	0.8	3
938	The Role of Natural and Semi-Synthetic Compounds in Ovarian Cancer: Updates on Mechanisms of Action, Current Trends and Perspectives. <i>Molecules</i> , 2023, 28, 2070.	1.7	4
939	Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6953-6966.	1.2	2
940	Prophylactic salpingectomy with delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in <i>BRCA1/2</i> mutation carriers: women's point of view. <i>Menopause</i> , 0, Publish Ahead of Print, .	0.8	0
950	Neoplasms of the Fallopian Tube and Broad Ligament. , 2023, , 287-342.		0
959	Gynecologic Pathology. , 2023, , 45-56.		0
961	Molecular testing in gynecologic cancer. , 2024, , 421-445.		0
964	Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine. , 2023, , 47-56.		0
966	Molecular Pathology of Ovarian Tumors. , 2023, , 271-296.		0
968	Serous Tumors, Pathology of the Ovary. <i>Encyclopedia of Pathology</i> , 2023, , 554-564.	0.0	0
974	Serous Tumours of the Ovary. , 2023, , 397-416.		0
975	Overview of Ovarian Tumours: Pathogenesis and General Considerations. , 2023, , 95-113.		0
976	Pathology of the Peritoneum. , 2023, , 575-610.		0
977	Gross Examination and Cut-Up of Surgical Specimens. , 2023, , 251-266.		0